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Cancer is a class of diseases characterized by out-of-control cell growth[1] .
The cells  grow and divide  without  space  without  respect  to  limits(aggressive),
invade and destroy adjacent tissues(invasive), and spread to others locations in the
body(metastatic).  These three malignant properties of cancers differentiate them
from benign tumors, which are self-limited in their growth and do not invade or
metastasize (spread or grow).
All  cancers  are  caused  by  abnormalities  in  genetic  material  of  the
transformed cells. These abnormalities may be due to the effects of carcinogens,
such as tobacco smoke, radiations, chemicals or infectious agents. Cancers cause
about 13% of all death.
Carcinogens  are  a  class  of  substances  that  are  directly  responsible  for
damaging DNA, promoting or aiding cancer[2]. Tobacco, asbestos, arsenic, radiation
such as gamma and x-rays, the sun, and compounds in car exhaust fumes are all
examples of carcinogens. When our bodies are exposed to carcinogens, free radicals
are formed that try to steal electrons from other molecules in the body. Theses free
radicals damage cells and affect their ability to function normally. Cancer can be the
result  of  a  genetic  predisposition  that  is  inherited  from  family  members.  It  is
possible to be born with certain genetic mutations or a fault in a gene that makes one
statistically more likely to develop cancer later in life. As the age increases , there is
an increase in the number of possible cancer-causing mutations in the DNA. This
makes age an important risk factor for cancer. Several viruses have also been linked
to cancer such as: human papilloma virus (a cause of cervical cancer), hepatitis B
and C (causes of liver cancer), and Epstein-Barr virus (a cause of some childhood
cancers). 
Human immunodeficiency virus (HIV) - and anything else that suppresses or
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weakens the immune system -  inhibits  the body's  ability  to  fight  infections and
increases the chance of developing cancer
Cancer harms the body when damaged cells divide uncontrollably to form
lumps or masses of tissue called tumors (except in the case of leukemia where
cancer  prohibits  normal  blood function  by abnormal  cell  division  in  the  blood
stream). Tumors can grow and interfere with the digestive, nervous, and circulatory
systems and they can release hormones that alter body function. Tumors that stay
in one spot and demonstrate limited growth are generally considered to be benign.
Cancer promoting oncogens are often activated in cancer cells, giving those
cells new properties, such as hyperactive growth and divisions, protection against
programmed cell death, loss of respect for normal tissue boundaries, and ability to
become established in diverse tissue environments. Tumor suppressor genes are
often inactivated in cancer cells, resulting in loss of normal functions in those cells,
such as  accurate  DNA replications,  control  over the  cell  cycle,  orientation and
adhesion  within  tissues,  and  interaction  with  protective  cells  of  the  immune
system.
A definitive diagnosis usually requires the histologic examination of a tissue
biopsy specimen by a pathologist, although the initial indication of malignancy can
be symptoms or radiography imaging abnormalities.  Most cancers can be treated
and  some  cured,  depending  on  the  specific  type,  location  and  stage.  Once
diagnosed cancer is usually treated with a combination of surgery, chemotherapy
and radiotherapy.
CANCER BIOLOGY:
The Cancer Biology portion of the site contains  in depth information about
the structure and function of normal cells and cancer cells.  The changes that make
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normal  cells  turn  into  cancer  cells  are  described. Cancer  systems  biology
encompasses the application of systems biology approaches to cancer research, in
order to study the disease as a complex adaptive system with emerging properties
at  multiple  biological  scales[3].  More  explicitly,  becausecancer  spans  multiple
biological, spatial and temporal scales, communication and feedback mechanisms
across  the  scales  create  a  highly  complex  dynamic  system.  The  relationships
between  scales  is  not  simple  or  necessarily  direct,  and  sometimes  become
combinatorial,  so  that  systems  approaches  are  essential  to  evaluate  these
relationships quantitatively and qualitatively.
Cancer systems biology therefore adopts a holistic view of cancer[4]. aimed
at integrating its many biological scales, including genetics, signaling networks[5],
epigenetics[6],  cellular  behavior,  histology,  (pre)clinical  manifestations  and
epidemiology.  Ultimately,  cancer  properties  at  one  scale,  e.g.,  histology,  are
explained by properties at  a scale below, e.g.,  cell behavior. Likewise, a higher
scale,  e.g.,  epidemiology,  can  encroach  on  a  lower  scale,  e.g.,  genetics.  The
fundamental  concept  is  that  percolation  of  properties  across  scales  must  be
measured and taken into account in order to fully understand etiology, progression
and dynamics of cancer. 
The systems biology approach relies heavily on the successes of decades of
reductionism, which has clarified the component parts and mechanistic principles
of living organisms, as well  as their key alterations in cancer, especially at the
genetic/genomic  scale,  to  deep  detail.  Basic  researchers  and  clinicians  have
progressively recognized the complexity of cancer and of its interaction with the
micro- and macro-environment, since putting together the components to provide a
cohesive view of the disease has been challenging and hampered progress. Cancer
Systems Biology transcends the “reductionist” approach to cancer that  typically
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produces causative explanations focused on a single gene or mutation, with little
emphasis on inter-scale relationships.
Biological Building Blocks:
Humans are made up of many millions of cells. In order to understand what
goes wrong in cancer, it is important to understand normal cells work. The first
step is to discuss the structure and basic functions of cells.         All living things,
including the cells that make up a human body are comprised of a small subset of





Additional biomolecules can be made by combining these four types. As an
example, many proteins are modified by the addition of carbohydrate chains. The
end product is called a glycoprotein.
Cells and Cell Structure:
The  tiny  cells  that  make  up  these  organs  actually  contain  within  them
smaller structures called organelles. Organelles are identified by microscopy, and
can also be purified  by cell  fractionation.  There are  many types of  organelles,
particularly in eukaryotic cells. While prokaryotes do not possess organelles per se,
some do contain protein-based microcompartments, which are thought to act as
primitive organelles[7].  These organelles  help the cells  to  perform their  jobs.  In
cancer, changes to these organelles can cause the individual cells and ultimately the
entire organism to have serious problems.
Cell Division and Mitosis:
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During a lifetime, many of the cells  that  make up the body age and die.
These cells must be replaced so that the body can continue functioning optimally
the reasons include the following:
• Sloughing off of epithelial cells such as those lining the skin and intestines.
The old, worn out cells on the surface of the tissues are constantly replaced.
A special  case  of  this  is  the monthly replacement  of  the cells  lining the
uterus in pre-menopausal women.
• Wound healing  requires  that  cells  in  the  area  of  the damage  multiply to
replace those lost. Viral diseases such as hepatitis may also cause damage to
organs that then need to replace lost cells.
• Replacement of the cells that make up blood. Red blood cells carry oxygen
to tissues. White blood cells such as B and T lymphocytes are part of the
body's immune system and help to ward off infections. Most of these cells
have very short lifespans and must be constantly replaced. The precursors of
these cells are located in bone marrow. These precursors, or stem cells, must
reproduce at  a very high rate to maintain adequate amounts of the blood
cells. The process by which a cell reproduces to create two identical copies
of itself is known as mitosis. The goal of mitosis is the formation of two
identical  cells  from a  single  parent  cell.  The  cells  formed  are  known as
daughter cells.
 
 In order for this to happen, the following must occur:
• The genetic material, the DNA in chromosomes, must be faithfully copied.
This occurs via a process known as replication.
• The  organelles,  such  as  mitochondria,  must  be  distributed  so  that  each
daughter cell receives an adequate amount to function.
• The cytoplasm of the cell must be physically separated into two different
cells.
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       Many of the features of cancer cells are due to defects in the genes that control
cell division. The cell division process occurs as an orderly progression through
four different stages. These four stages are collectively known as the cell cycle.
Gene Function:
The  chromosomes  within  our  cells  contain  an  enormous  amount  of
information. It  is  estimated that humans have somewhere around 30,000 genes.
Each gene codes for an RNA molecule that is either used directly or used as a
guide for the formation of a protein such as the insulin shown earlier. Information
in our cells generally flows in a predictable order from the storage form of the
information  (DNA)  through  the  working  form  (RNA)  into  the  final  product
(protein).   DNA is used as a guide or template for the production of more DNA.
This process, known as replication, is addressed in the section on cell division. The
process in which particular sections of DNA (genes) are used to produce RNA is
known  as transcription.  We  will  cover  transcription  in  some  detail  because
alterations  in  the  transcription  of  certain  genes  are  very  important  in  the
development of cancer. The set of genes that are 'on' at any given time is critical.
The variable environment in which we live means that different genes need to be
'on' at different times. For example, if a meal contains large amounts of lactose, a
sugar found in milk, then our bodies respond by turning on (transcribing) the genes
that lead to the production of enzymes that break down lactose. If a different sugar
or nutrient is present, the correct genes need to be turned on to process it.
Mutation:
Cancer is a result of the breakdown of the controls that regulate cells. The
causes  of  the  the  breakdown  always  include  changes  in  important  genes.  The
changes  are  often  the  result  of  mutations,  changes  in  the  DNA sequence  of
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chromosomes.  Mutations  can  be  very  small  changes,  affecting  only  a  few
nucleotides or they can be very large, leading to major changes in the structure of
chromosomes. Due to  the  damaging  effects  that  mutations  can  have on  genes,
organisms have mechanisms such as DNA repair to prevent or correct (revert the
mutated sequence back to its original state) mutations[8].
Both  small  and  large  mutations  can  affect  the  behavior  of  cells.
Combinations  of  mutations  in  important  genes  can lead  to  the  development  of
cancer. The material covered in these sections describes the relationship between
mutation and cancer, the different kinds of mutations and what causes them.
Cancer Genes:
The cell division process is dependent on a tightly controlled sequence of
events.  These  events  are  dependent  on  the  proper  levels  of  transcription  and
translation  of  certain  genes.  When  this  process  does  not  occur  properly,
unregulated cell growth may be the end result. Of the 30,000 or so genes that are
currently thought to exist in the human genome, there is a small subset that seems
to be particularly important in the prevention, development,  and progression of
cancer.  These  genes  have  been  found  to  be  either  malfunctioning  or  non-
functioning in many different kinds of cancer.The genes that have been identified
to date have been categorized into two broad categories, depending on their normal
functions  in  the  cell.  Genes  whose  protein  products  stimulate  or  enhance  the
division and viability of cells. 
This first category also includes genes that contribute to tumor growth by
inhibiting  cell  death.  Genes  whose  protein  products  can  directly  or  indirectly
prevent cell division or lead to cell death.The normal versions of genes in the first
group are called proto-oncogenes. The mutated or otherwise damaged versions of
these genes are called oncogenes.




Cancer is the result of unregulated cell division.  Cancer cells divide when
they are not supposed to, don't stop dividing when they are supposed to and don't
die when they should.  In the worst cases, the cancer cells leave the area in which
they arose and travel to other parts of the body.
In cancer cells, changes to key genes cause the cells to act abnormally. The
changes  are  often  the  result  of  changes  to  the  DNA (mutations)  in  the  cells.
Because there are many different things that are capable of causing mutation, there
are an equally large number of causes of cancer.
The development of cancer takes place in a multi-step process. As the cells
become more abnormal, they gain new capabilities, such as the ability to release
growth  factors  and digestive  enzymes.  The  cells  continue  to  divide,  impacting
nearby  normal  cells,  often  reducing  the  function  of  the  affected  organ.   Even
abnormal cancer cells die sometime and a tumor that is large enough to feel can
take years to reach that size. Although not all cancers share exactly the same steps,
there are some general features that are shared in the development of many types
of cancer. Another critical step in the growth of a tumor is the development of a
blood supply (angiogenesis). Blood provides nutrients, carries away waste and the
blood vessels provide a way for cancer cells to move around the body.
Angiogenesis:
Angiogenesis is the physiological process through which new blood vessels
form from pre-existing vessels. This is distinct from vasculogenesis, which is the
de novo formation of endothelial cells from mesoderm cell precursors[9].The first
vessels  in  the  developing  embryo  form  through  vasculogenesis,  after  which
angiogenesis  is  responsible  for  most,  if  not  all,  blood  vessel  growth  during
development and in disease[10].
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All cells need a constant source of oxygen and nutrients such as glucose
(sugar). Our cells get their nutrients delivered to them via the blood. Nutrients and
oxygen  are  pumped  through  the  body via  the  circulatory  system.  Once  in  the
tissues, the nutrients cross the blood vessel walls and enter the spaces around the
cells.
Cells need nutrients constantly, and the process by which nutrients float over
to cells takes time. In order to make sure that all cells get enough nutrients, our
tissues are full of many small blood vessels (capillaries) that can deliver food to
within a very short distance of any cell.Even though cancer cells are abnormal,
they still require oxygen and nutrients.  The development of blood vessels is an
essential step in the growth of a tumor. Without vessels tumors cannot grow to be
larger than a small fraction of an inch .When the area around the cells in a tumor
starts to get too far from a blood vessel, the oxygen and nutrient levels start to go
down. A decrease in oxygen is also called hypoxia.  Hypoxia triggers changes in
the behavior of the tumor cells.The tumor cells produce (or cause nearby cells to
produce) growth factors that stimulate the formation of blood vessels.  Tumors that
do not produce (or cause other cells to produce) angiogenesis factors cannot grow.  
One of the most well-studied angiogenesis factors is called vascular endothelial
derived growth factor (VEGF).  VEGF or other angiogenesis factors produced by
tumor cells or nearby cells can cause the development of blood vessels that feed
the growing tumor.  Because VEGF is a normal signal for the cells forming the
blood vessels, they are really just doing their job. 
The  tumor  'tricks'  the  body into  creating  new blood  vessels.  The  blood
vessels  created in  this  way are  not  exactly the same as  normal  blood vessels. 
Frequently they are less organized and leakier than normal vessels.
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Abnormal angiogenesis is not limited to cancer.  Other diseases, including
macular  degeneration,  a  progressive  eye  disease,  are  linked  to  abnormal
development of blood vessels.
Metastasis:
Metastasis is responsible for the great majority of deaths in cancer patients.
It is the spread of a cancer from one organ or part to another non-adjacent organ or
part.  The  new  occurrences  of  disease  thus  generated  are  referred  to  as
metastases[11].  Metastasis is the process by which cancer cells migrate throughout
the  body.  In  order  for  cells  to  move  through  the  body,  they  must  first  climb
over/around neighboring cells. They do this by rearranging their cytoskeleton and
attaching to the other cells and the extracellular matrix via proteins on the outside
of their plasma membranes. By extending part of the cell forward and letting go at
the back end, the cells can migrate forward. The cells can crawl until they hit a
blockage which cannot be bypassed. Often this block is a thick layer of proteins
and glycoproteins  surrounding the  tissues,  called  the basal  lamina  or  basement
membrane. In order to cross this layer, cancer cells secrete a mixture of digestive
enzymes that degrade the proteins in the basal lamina and allow them to crawl
through.The proteins secreted by cancer cells contain a group of enzymes called
matrix metalloproteases (MMP). These enzymes act as 'molecular scissors' to cut
through the proteins that inhibit the movement of the migrating cancer cells. Once
the cells  have traversed the basal lamina,  they can spread through the body in
several ways. They can enter the bloodstream by squeezing between the cells that
make up the blood vessels. Once in the blood stream, the cells float through the
circulatory  system until  they find  a  suitable  location  to  settle  and  re-enter  the
tissues.  The cells  can then begin to  grow in this  new location,  forming a new
tumor. The process of metastasis formation is very inefficient process but leads to
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the majority of deaths associated with cancer. This is because the number of cells
that leave a tumor can be in the millions per day.
Even if  only a  small  fraction of  the cells  that  leave a tumor are able to
survive to form a new tumor, the large number of attempts means that a distant
growth is  likely to  occur  at  some point  Migrating  cancer  cells  can die from a
variety of causes.
The causes includes:
 Cells normally live tightly connected to their neighbors and the meshwork of
proteins surrounding them. Detachment from the surface of other cells can
lead to cell death.
 Cancer cells are often quite large in comparison to the cells that normally
live in the lymphatic system or blood system. When they travel through the
vessels they can get damaged or stuck, leading to cell death.
 Cancer cells can be recognized and destroyed by cells of the immune system
Additionally, it is important to note that even if a cancer cell does not die, it
does not mean that it will form a tumor. The cells may exist at locations far from
the original tumor without multiplying enough to cause any problems.
Tumor-Host Interactions[12]:
Tumors are surrounded by resident non-cancerous cells, connective tissue,
and extracellular  matrix.  These  components  are  known as  the  tumor  stroma or
microenvironment. Within the past several years, it has become evident that the
tumor  microenvironment  plays  an  important  role  in  both  tumor  initiation  and
progression.  Due to  this  new knowledge,  researchers  have begun to investigate
treatments that target both the cancer and its surroundings.
Immune System:
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The immune system consists of a large number of different types of cells and
proteins  that  function  to  distinguish  between  normal  and  abnormal  cellular
components and between 'self' and 'non-self'. As an example, when a thorn gets
stuck in the body, the immune cells are able to recognized the thorn as a foreign
object (i.e. 'non-self') and attack it. The same is true for bacteria, viruses or other
organisms that can invade our bodies. More subtle distinction between self and
non-self  occurs in  the recognition of  cancer cells  by the forces of  the immune
system. The cancer cells are recognized and attacked because they differ from the
normal  'self'  from  which  they  arose.  The  main  cells  of  the  specific  immune
response  are  lymphocytes  -  B  cells  and  T  cells.  All  lymphocyte  precursors
originate in the bone marrow. The pre-B cells stay in the bone marrow to undergo
further  development,  while  the  T cell  precursors  migrate  to  an  immune  organ
located in the neck (the thymus) to further develop. In fact, T cells get their name
from the  thymus.  For  trivia  buffs:  B  cells  are  named  after  an  organ  found  in
chickens (the bursa of Fabricius) where they were first studied. Humans do not
have an equivalent organ.Early in T cell and B cell development, developing cells
that strongly react with normal cell proteins are removed from the system. In this
way, the immune system ensures that the B cells and T cells do not kill normal
body cells. If self-reactive T cells and B cells are not removed from the lymphocyte
population, autoimmune diseases like lupus or rheumatoid arthritis may develop. 
There are two classes of mature T cells:
• Helper  T  cells-  These  cells  help  other  immune  cells,  including  CTLs,
macrophages and B cells, carry out their functions more efficiently.
• Cytotoxic T Lymphocytes (CTL)-(cyto=cell and toxic because they can kill)
These are cells that are able to kill other cells, they are cellular assasins.
They directly kill  any cell  that they recognize as abnormal, such as cells
infected with viruses or cancer cells.
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The immature T cells residing in the lymph nodes and spleen do not mature
into full effectors cells until an APC comes to them and shows them, or presents to
them, a particular protein antigen. Once the T cell is notified by the APC that there
are cells in the body expressing these abnormal proteins, the T cells mature and
leave  the  lymph  nodes  and  the  spleen  to  circulate  in  the  body  and  find  the
abnormal cells. When the T cells find the abnormal cells they are able to kill them.
In the case of virus infection, killing the infected cell is a harsh but effective way to
limit the production of the viruses within. Cancer cells may also be recognized and
eliminated by cytotoxic cells of the immune system.
 B cells are another critical component of the acquired immune response. 
Like T cells, B cells are formed in the bone marrow.  The cells move out into the
body to  mature.  B cells  are responsible  for  producing antibodies,  proteins  that
recognize  foreign  objects  that  enter  the  body (viruses,  bacteria,  other  proteins,
etc.).  
B cells can recognize different targets.There are millions of different kinds
of  B cells  in  our  bodies  and our  immune  system can  respond  to  a  very large
number of different 'foreign' targets.The immune system functions as an effective
surveillance system to eliminate abnormal cells and invading organisms from our
bodies.
PROGNOSIS:
Cancer has a reputation as a deadly disease. Taken as a whole, about half of
people receiving treatment  for  invasive cancer (excluding carcinoma in situ and
non-melanoma skin cancers) die from cancer or its treatment[13]. Survival is worse
in the developing world . However, the survival rates vary dramatically by type of
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cancer, with the range running from basically all people surviving to almost no one
surviving.
Those  who  survive  cancer  are  at  increased  risk  of  developing  a  second
primary cancer at about twice the rate of those never diagnosed with cancer[14]. The
increased risk is believed to be primarily due to the same risk factors that produced
the first  cancer,  partly due to  the treatment  for the first  cancer,  and potentially
related to better compliance with screening.
Predicting either short-term or long-term survival is difficult and depends on
many factors. The most important factors are the particular kind of cancer and the
patient's  age  and  overall  health.  People  who  are frail with  many  other  health
problems have lower survival rates than otherwise healthy people. A centenarian is
unlikely to survive for five years even if the treatment is successful. People who
report a higher quality of life tend to survive longer[15]. 
 People  with  lower  quality  of  life  may  be  affected  by major  depressive
disorder and other complications from cancer treatment and/or disease progression
that  both  impairs  their  quality  of  life  and  reduces  their  quantity  of  life.
Additionally, patients with worse prognoses may be depressed or report a lower
quality of life directly because they correctly perceive that their condition is likely
to be fatal.
EPIDEMIOLOGY:
 In U.S and other developed countries, cancer is presently responsible for
about 20 %of all death. On the yearly basis, 0.9% of the population is diagnosed
with cancer.  In 2008, it was estimated that there are just over two million people
living with or beyond cancer in the UK who had previously been diagnosed, and
this is predicted to rise by more than 3% a year. Prevalence figures are influenced
by both incidence and survival. Thus, the most prevalent types of cancer are those
with a relatively high incidence rate and a good prognosis. In the UK the most
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prevalent cancer in males is prostate cancer and in females it is breast cancer. The
latest analysis shows that at the end of 2006, there were over 200,000 prevalent
cancer patients in the UK who were alive one year after their diagnosis. In total,
there were 1.13 million cancer survivors in the UK who were alive up to 10 years
from diagnosis at the end of 2006.
 These  latest  estimates  are much higher than previous forecasts  of  cancer
prevalence because incidence has been rising whilst the death rates have continued
to fall,  leading to better survival. This is expected to continue over the coming
years as a result of a number of factors, including an ageing population, earlier
detection of cancer and continued improvements in treatment. In India, the number
of new breast cancer cases is about 115,000 per year and this is expected to rise to
250,000 new cases per year by 2015. Some slow-growing cancers are particularly
common. Autopsy studies in Europe and Asia have shown that up to 36% of people
have  undiagnosed  and  apparently  harmless thyroid  cancer at  the  time  of  their
deaths, and that 80% of men develop prostate cancer by age 80. As these cancers
did not  cause the person's death,  identifying them would have represented over
diagnosis rather  than  useful  medical  care.  The  three  most  common childhood
cancers  are  leukemia (34%), brain tumors (23%), and lymphomas (12%)[16]. Rates
of childhood cancer have increased by 0.6% per year between 1975 to 2002 in the
United States[17] .
CLASSIFICATION:
Tumor  grade  is  a  system  used  to  classify cancer cells  in  terms  of  how
abnormal they look under a microscope and how quickly the tumor is likely to
grow and spread.  Many factors  are  considered  when determining  tumor  grade,
including the structure and growth pattern of the cells. The specific factors used to
determine tumor grade vary with each type of cancer. Histologic grade, also called
differentiation, refers to how much the tumor cells resemble normal cells of the
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same tissue type. Nuclear grade refers to the size and shape of the nucleus in tumor
cells and the percentage of tumor cells that are dividing. Tumor grade should not
be confused with the stage of a cancer. Cancer stage refers to the extent or severity
of the cancer, based on factors such as the location of the primary tumor, tumor
size, number of tumors, and lymph node involvement (spread of cancer into lymph
nodes).  If a tumor is suspected to be malignant, a sample of tissue or the entire
tumor in a procedure called a biopsy and is the tissue is examined to determine
whether the tumor is benign or malignant. Based on the microscopic appearance of
cancer cells, it is commonly described tumor grade by four degrees of severity:
Grades 1, 2, 3, and 4. The cells of Grade 1 tumors resemble normal cells, and tend
to grow and multiply slowly. Grade 1 tumors are generally considered the least
aggressive in behavior. Conversely, the cells of Grade 3 or Grade 4 tumors do not
look like normal cells of the same type. Grade 3 and 4 tumors tend to grow rapidly
and spread faster than tumors with a lower grade. Grading systems are different for
each type of cancer. For example, pathologists use the Gleason system to describe
the  degree  of  differentiation  of prostate  cancer cells.  The  Gleason  system uses
scores ranging from Grade 2 to Grade 10. Lower Gleason scores describe well-
differentiated, less aggressive tumors. Higher scores describe poorly differentiated,
more  aggressive  tumors.  Other  grading  systems  include  the  Bloom-Richardson
system for breast  cancer and the Fuhrman system for kidney cancer. Use tumor
grade  and  many other  factors,  such  as  cancer  stage,  to  develop  an  individual
treatment plan for the patient and to predict the patient's prognosis. Generally, a
lower grade indicates a better prognosis (the likely outcome or course of a disease;
the chance of recovery or recurrence).                                                                    
However,  the  importance  of  tumor  grade  in  planning  treatment  and
estimating a patient's prognosis is greater for certain types of cancers, such as soft
tissue sarcoma, primary brain tumors, lymphomas, and breast and prostate cancer.
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Patients should speak with their doctor about tumor grade and how it relates to
their diagnosis and treatment. 
Cancers are classified by the type of cell that the tumor cells resemble and is
therefore presumed to be the origin of the tumor.
These types include: 
Carcinomas:  malignant  tumor  derived  from  cells  (epithelial  cells)  that  cover
internal  and  external  parts  of  the  body.  Eg.  common  cancers  including   lung,
prostrate, breast, and colon cancer   
Sarcomas: malignant tumor derived from cells that are located in bone, cartilage,
fat, connective tissue, muscle, and other supportive tissues.             
Lymphomas are  cancers  that  begin  in  the  lymph  nodes  and  immune  system
tissues[19].                                                                                                   
Leukemias are cancers that begin in the bone marrow and often accumulate in the
bloodstream[19].                                                               
Germ cell tumor: tumors derived from totipotent cells. In adults most often found
in testicles and ovary; in fetuses, babies and children mostly often found on the
body midline.                                                                              
Adenomas are cancers that arise in the thyroid, the pituitary gland, the adrenal
gland, and other glandular tissues.                                                               
Blastic tumor: A tumor which resembles an immature embryonic               
CAUSES OF CANCER:
Cancers  are  primarily  an  environmental  disease  with  90–95%  of  cases
attributed to environmental factors and 5–10% due to genetics. Environmental, as
used by cancer researchers, means any cause that is not inherited genetically, not
merely pollution[20]. Common environmental factors that contribute to cancer death
include tobacco (25–30%), infections (15–20%),  radiation (both ionizing and non-
ionizing,  up  to  10%),  stress,  lack  of   physical  activity,  and environmental
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pollutants. It is nearly impossible to prove what caused a cancer in any individual,
because most cancers have multiple possible causes. 
For example, if a person who uses tobacco heavily develops lung cancer,
then it was probably caused by the tobacco use, but since everyone has a small
chance of developing lung cancer as a result of air pollution or radiation, then there
is a small chance that the cancer developed because of air pollution or radiation[21].
Chemicals:                                                                                                       
Cancer  pathogenesis  is  traceable  back  to DNA mutations that  impact  cell
growth  and  metastasis.  Substances  that  cause  DNA mutations  are  known  as
mutagens, and mutagens that cause cancers are known as carcinogens. Particular
substances  have  been  linked  to  specific  types  of  cancer.Tobacco  smoking is
associated  with  many  forms  of  cancer,  and  causes  90%  of lung  cancer[22].
Many mutagens are  also carcinogens,  but  some  carcinogens  are  not
mutagens. Alcohol is  an  example  of  a  chemical  carcinogen  that  is  not  a
mutagen[23].Cancer related to one's occupation is believed to represent between 2–
20% of all cases[24]. Every year, at least 200,000 people die worldwide from cancer
related  to  their  workplace[25].  Most  cancer  deaths  caused  by  occupational  risk
factors occur in the developed world. It  is  estimated that approximately 20,000
cancer deaths and 40,000 new cases of cancer each year in the U.S. are attributable
to occupation[26]. Millions of workers run the risk of developing cancers such as
lung cancer and mesothelioma from inhaling asbestos fibers and tobacco smoke, or
leukemia from exposure to benzene at their workplaces.
Diet and exercise:                                                               
Diet, physical inactivity, and obesity are related to approximately 30–35% of
cancer deaths[27]. In the United States excess body weight is associated with the
development  of  many types of  cancer and is  a  factor  in  14–20% of all  cancer
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deaths. Physical inactivity is believed to contribute to cancer risk not only through
its  effect  on  body  weight  but  also  through  negative  effects  onimmune
system and endocrine  system.  More  than  half  of  the  effect  from  diet  is  due
to overnutrition rather than from eating too little healthy foods. Diets that are low
in  vegetables,  fruits  and  whole  grains,  and  high  in processed or  red  meats  are
linked  with  a  number  of  cancers.  A  high-salt diet  is  linked  to gastric
cancer, aflatoxin  B1,  a  frequent  food  contaminate,  with  liver  cancer,  and Betel
nut chewing  with  oral  cancer[28].  This  may  partly  explain  differences  in  cancer
incidence in different countries. For example, gastric cancer is more common in
Japan due to its high-salt diet[29] and colon cancer is more common in the United
States.  Immigrants  develop  the  risk  of  their  new  country,  often  within  one
generation, suggesting a substantial link between diet and cancer[30].
Infection:
Worldwide  approximately  18% of  cancer  deaths  are  related  to infectious
diseases[31]. This proportion varies in different regions of the world from a high of
25% in Africa  to  less  than 10% in  the  developed world.  Viruses are  the usual
infectious  agents  that  cause  cancer  but bacteria and parasites may  also  have  an
effect. A virus that can cause cancer is called an oncovirus. These include human
papillomavirus (cervical  carcinoma),  Kaposi's  sarcoma  herpesvirus (Kaposi's
sarcoma and  primary  effusion  lymphomas), hepatitis  B and hepatitis  C viruses
(hepatocellular carcinoma), and Human T-cell leukemia virus-1(T-cell leukemias).
Bacterial infection may also increase the risk of cancer, as seen in Helicobacter
pylori-induced gastric  carcinoma[32].  Parasitic  infections strongly associated with
cancer  include Schistosoma  haematobium (squamous  cell  carcinoma  of  the
bladder)  and  the liver  flukes, Opisthorchis  viverrini and Clonorchis
sinensis (cholangiocarcinoma). 
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Radiation:                                                                 
Up to 10% of invasive cancers are related to radiation exposure, including
both ionizing  radiation and non-ionizing ultraviolet  radiation[33].  Additionally,  the
vast majority of non-invasive cancers are non-melanoma skin cancers caused by
non-ionizing ultraviolet  radiation.  Sources  of  ionizing  radiation  include medical
imaging, and radon gas. Radiation can cause cancer in most parts of the body, in all
animals, and at any age, although radiation-induced solid tumors usually take 10–
15 years, and can take up to 40 years, to become clinically manifest, and radiation-
induced leukemias typically require 2–10 years to appear[34].  Some people, those
with nevoid basal cell carcinoma syndrome or retinoblastoma, are more susceptible
than  average  to  developing  cancer  from  radiation  exposure.   Children  and
adolescents are twice as likely to develop radiation-induced leukemia as adults;
radiation exposure before birth has ten times the effect. Ionizing radiation is not a
particularly strong mutagen. Residential exposure to radon gas, for example, has
similar cancer risks as passive smoking. Low-dose exposures, such as living near
a nuclear power plant, are generally believed to have no or very little effect on
cancer  development.  Radiation  is  a  more  potent  source  of  cancer  when  it  is
combined  with  other  cancer-causing  agents,  such  as  radon  gas  exposure  plus
smoking  tobacco.   Unlike  chemical  or  physical  triggers  for  cancer,  ionizing
radiation  hits  molecules  within  cells  randomly.  If  it  happens  to  strike
a chromosome,  it  can  break  the  chromosome,  result  in  an abnormal  number  of
chromosomes, inactivate one or more genes in the part of the chromosome that it
hit, delete parts of the DNA sequence, cause chromosome translocations, or cause
other types of chromosome abnormalities.  
Damage normally results in the cell dying, but smaller damage may leave a
stable, partly functional cell that may be capable of proliferating and developing
into cancer, especially if tumor suppressor genes were damaged by the radiation.
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Three independent  stages appear  to  be involved in  the creation  of  cancer  with
ionizing  radiation:  morphological  changes  to  the  cell,  acquiring cellular
immortality (losing normal, life-limiting cell regulatory processes), and adaptations
that favor formation of a tumor. Even if the radiation particle does not strike the
DNA directly, it triggers responses from cells that indirectly increase the likelihood
of mutations. Medical use of ionizing radiation is a growing source of radiation-
induced cancers. Ionizing radiation may be used to treat other cancers, but this
may, in some cases, induce a second form of cancer. It is also used in some kinds
of medical imaging. One report estimates that approximately 29,000 future cancers
could be related to the approximately 70 million CT scans performed in the US in
2007. It is estimated that 0.4% of cancers in 2007 in the United States are due to
CTs performed in the past and that this may increase to as high as 1.5–2% with
rates of CT usage during this same time period. Prolonged exposure to ultraviolet
radiation from the sun can lead to melanoma and other skin malignancies[35]. Clear
evidence  establishes  ultraviolet  radiation,  especially  the  non-ionizing  medium
wave UVB, as the cause of most non-melanoma skin cancers, which are the most
common  forms  of  cancer  in  the  world.  Non-ionizing radio  frequency radiation
from mobile phones, electric power transmission, and other similar sources have
been  described  as  a possible  carcinogen by  the World  Health
Organization's International Agency for Research on Cancer[36].  
Heredity:
The  vast  majority  of  cancers  are  non-hereditary  ("sporadic  cancers").
Hereditary cancers are primarily caused by an inherited genetic defect. Less than
0.3% of the population are carriers of a genetic mutation which has a large effect
on  cancer  risk  and  these  cause  less  than  3–10%  of  all  cancer[37].  Some  of
these syndromes include:  certain  inherited  mutations  in  the  genes BRCA1 and
BRCA2 with  a  more  than  75%  risk  of breast  cancer and ovarian  cancer,
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and hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome) which
is present in about 3% of people with colorectal cancer[38], among others.
Physical agents:
Some substances cause cancer primarily through their physical, rather than
chemical, effects on cells[39]. A prominent example of this is prolonged exposure
to asbestos,  naturally  occurring  mineral  fibers  which  are  a  major  cause
of mesothelioma, which is  a cancer of the serous membrane,  usually the serous
membrane surrounding the lungs[40].  Other substances in this category, including
both  naturally  occurring  and  synthetic  asbestos-like  fibers  such
as wollastonite, attapulgite, glass wool, and rock wool, are believed to have similar
effects.  Non-fibrous  particulate  materials  that  cause  cancer  include  powdered
metallic cobalt and nickel,  and crystalline  silica (quartz, cristobalite,
and tridymite).  Usually,  physical  carcinogens must get  inside the body (such as
through inhaling tiny pieces) and require years of exposure to develop cancer. 
Physical trauma resulting in cancer is relatively rare. Claims that breaking
bones resulted in bone cancer, for example, have never been proven.  Similarly,
physical trauma is not accepted as a cause for cervical cancer, breast cancer, or
brain cancer[41].
One accepted source is frequent, long-term application of hot objects to the
body. It is possible that repeated burns on the same part of the body, such as those
produced  by  charcoal hand  warmers,  may  produce  skin  cancer,  especially  if
carcinogenic chemicals are also present. Frequently drinking scalding hot tea may
produce esophageal cancer. Generally, it is believed that the cancer arises, or a pre-
existing cancer is encouraged, during the process of repairing the trauma, rather
than the cancer being caused directly by the trauma. However, repeated injuries to
the  same  tissues  might  promote  excessive  cell  proliferation,  which  could  then
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increase the odds of a cancerous mutation. There is no evidence that inflammation
itself causes cancer. 
Hormones:
Some hormones play a role in the development of cancer by promoting cell
proliferation[42].  Insulin-like growth factors and their binding proteins play a key
role in cancer cell proliferation, differentiation and apoptosis, suggesting possible
involvement in carcinogenesis[43]. 
 Hormones are important agents in sex-related cancers such as cancer of the
breast, endometrium,  prostate,  ovary,  and testis,  and  also  of thyroid
cancer and bone cancer. For example,  the daughters of women who have breast
cancer  have  significantly  higher  levels  of estrogen and progesterone than  the
daughters  of  women  without  breast  cancer.  These  higher  hormone  levels  may
explain why these women have higher risk of breast cancer, even in the absence of
a breast-cancer gene. Similarly, men of African ancestry have significantly higher
levels of testosterone than men of European ancestry, and have a correspondingly
much higher level of prostate cancer. Men of Asian ancestry, with the lowest levels
of  testosterone-activating androstanediol  glucuronide,  have  the  lowest  levels  of
prostate cancer. obese people have higher levels of some hormones associated with
cancer and a higher rate of those cancers. Women who take hormone replacement
therapyhave a higher risk of developing cancers associated with those hormones.
On the other hand, people who exercise far more than average have lower levels of
these  hormones,  and  lower  risk  of  cancer. Osteosarcoma may  be  promoted
by growth  hormones. Some  treatments  and  prevention  approaches  leverage  this
cause  by artificially  reducing  hormone  levels,  and  thus  discouraging  hormone-
sensitive cancers.





Excepting  the  rare  transmissions  that  occur  with  pregnancies  and only a
marginal few organ donors, cancer is  generally not a transmissible disease. The
main reason for this is tissue graft rejection caused by MHC incompatibility[44]. In
humans  and  other  vertebrates,  the  immune  system  uses  MHC  antigens  to
differentiate  between  "self"  and  "non-self"  cells  because  these  antigens  are
different  from person  to  person.  When  non-self  antigens  are  encountered,  the
immune system reacts  against  the appropriate cell.  Such reactions may protect
against tumour cell engraftment by eliminating implanted cells.
In  the  United  States,  approximately  3,500  pregnant  women  have  a
malignancy  annually,  and  transplacental  transmission  of  acute lymphoma,
melanoma and carcinoma from  mother  to  fetus  has  been  observed.  The
development of donor-derived tumors from organ transplants is exceedingly rare.
The  main  cause  of  organ  transplant  associated  tumors  seems  to  be  malignant
melanoma, that was undetected at the time of organ harvest. 
PATHOPHYSIOLOGY:
Cancers are caused by series of mutations. Cancer is fundamentally a disease
of regulation of tissue growth. In order for a normal cell to transform cell into a
cancer  cell  growth  and differentiation  must  be  altered[45] .Genetic  changes  can
occur at many levels, of entire chromosomes to a mutation affecting a single DNA
nucleotide.  Malignant  transformation can  occur  through the  formation of  novel
oncogenes,  the  inappropriate  over-expression  of  normal  oncogenes,  or  by  the
under-expression  or  disabling of  tumor suppressor  genes.  Typically,  changes in
many genes are required to transform a normal cell into a cancer cell[46]. There are
two broad categories of genes which are affected by these change:




An oncogene is a gene that, when mutated or expressed at high levels, helps
turn  a  normal  cell  into  a  tumor  cell.  Many  abnormal  cells  normally  undergo  a
programmed form of death (apoptosis). Activated oncogenes can cause those cells to
survive and proliferate instead. Most oncogenes require an additional step, such as
mutations in another gene, or environmental factors, such as viral infection, to cause
cancer. Oncogens promotes cell growth through a variety of ways. Many can produce
harmones, a "chemical messenger" between cell which encourage mitosis, the effects
of which depends on the signal transduction of the receiving tissues or cells.  In other
words,  when  a  hormone  receptor  on  a  recipient  cell  is  stimulated,  the  signal  is
conducted  from  the  cell  to  the  cell  nucleus  to  effect  some  change  in  gene
transcription regulation at  nuclear  level.  Mutations in  proto-oncongens,  which are
normal gene that can become an oncogene due to mutations or increased expression.
Proto-oncogenes code  for  proteins  that  help  to  regulate  cell  growth  and
differentiation. They can become an oncogene by a relatively small modification of
its  original  function.  After  this  the  proto-oncogens  become  oncogens,  and  this
transition  upsets  the  normal  balance  of  cell  cycle  regulation  in  the  cell,  making
uncontrolled  growth  possible.  One  of  the  first  oncogen  to  be  defined  in  cancer
research is the ras oncogens. mutation of this family of proto oncogene are more
common being found in 20% to 30% of all human tumors.
Tumor suppressor genes:
These genes normally inhibit cell division and prevent survival of cells that
have damaged DNA. In patients  with  cancer  these tumor suppressor  genes are
often  disabled.  This  is  caused  by cancer-promoting  genetic  changes.  Typically,
changes in many genes are required to transform a normal cell into a cancer cell.
often DNA damage will cause the presence of free floating genetic material as well
as other signs, and will trigger enzymes and pathways which lead to the activation
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of tumor suppressor genes. the function of such gene is to arrest the progression of
the cell  cycle in  order carry out  DNA repair,  preventing mutations from being
passed  on  to  the  daughter  cells.  However  the  mutation  can  damage the  tumor
suppressor genes itself, or the signal pathway which activates it, "switching it off".
Thus the DNA repair is hindered or inhibited: DNA damages accumulate without
repair leading to cancer.
SYMPTOMS OF CANCER:
Cancer  symptoms  are  quite  varied  and  depend  on  where  the  cancer  is
located, where it has spread, and how big the tumor is. Some cancers can be felt or
seen through the skin - a lump on the breast or testicle can be an indicator of cancer
in those locations. Skin cancer (melanoma) is often noted by a change in a wart or
mole on the skin. Some oral cancers present white patches inside the mouth or
white spots on the tongue. Other cancers have symptoms that are less physically
apparent. Some brain tumors tend to present symptoms early in the disease as they
affect  important  cognitive  functions.  Pancreas  cancers  are  usually  too  small  to
cause symptoms until they cause pain by pushing against nearby nerves or interfere
with  liver  function  to  cause  a  yellowing of  the  skin  and eyes  called  jaundice.
Symptoms also can be created as a tumor grows and pushes against organs and
blood vessels. For example, colon cancers lead to symptoms such as constipation,
diarrhea, and changes in stool size. Bladder or prostate cancers cause changes in
bladder function such as more frequent or infrequent urination. As cancer cells use
the body's energy and interfere with normal hormone function, it  is  possible to
present  symptoms  such  as  fever,  fatigue,  excessive  sweating,  anemia,  and
unexplained  weight  loss.  When  cancer  spreads,  or  metastasizes,  additional
symptoms can present themselves in the newly affected area. Swollen or enlarged
lymph nodes are common and likely to be present early. If cancer spreads to the
brain, patients may experience vertigo, headaches, or seizures. Spreading to the
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lungs may cause coughing and shortness of breath. 
In addition, the liver may become enlarged and cause jaundice and bones
can become painful, brittle, and break easily. Symptoms of metastasis ultimately
depend on the location to which the cancer has spread.
Symptom control:
Although the control of the symptoms of cancer is not typically thought of
as a treatment directed at the cancer, it is an important determinant of quality of life
of cancer patients, and plays an important role in the decision whether the patient is
able  to  undergo  other  treatments.  Pain  medications  such  as  morphine  and
oxycodone  and  antiemetics,  drugs  to  suppress  nausea  and  vomiting  are  very
commonly used in patients.
DIAGNOSIS:
Most  cancers  are  initially  recognized  by  signs  or  symptoms  appear  or
through screening. Neither of these lead to definitive diagnosis. There are several
methods  of  diagnosing  cancer.  With  advances  in  technologies  that  understand
cancers better, there is a rise of number of diagnostic tools that can help detect
cancers.  Once  suspected,  diagnosis  is  usually  made  by  pathologists  and
oncopathologists  and  imaging  radiologists.  Some  types  of  cancer,  particularly
lymphomas, can be hard to classify, even for an expert.
 The most common diagnostic methods include:
• Biopsy
This is a test where a small sample of tissue is taken from the suspected
cancer with the help of a fine tipped needle (fine needle aspiration – FNA), or with
a thicker hollow needle (core biopsy) or by surgical excision. The tissues are then
examined under a microscope for the presence of cancer cells. Depending on tumor
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location,  some  biopsies  can  be  done  on  an  outpatient  basis  with  only  local
anesthesia.
• Sentinel node biopsy
This is a procedure where the closest  and most important nodes near the
cancer  are  surgically  excised  and  examined.  Since  sentinel  nodes  are  the  first
location that cancer is likely to spread, only these lymph nodes that likely contain
cancer cells.
• Endoscopy
In this imaging technique a thin, flexible tube with a tiny camera on the end
is inserted into the body cavities. This allows the doctors to view the suspicious
area. There are many types of scopes, each designed to view particular areas of the
body
• Blood tests
Blood tests can be performed to detect the normal blood cells as well as for
specific  tumor  markers.  Some tumors release substances called  tumor markers,
which can be detected in the blood. A blood test for prostate cancer determines the
amount  of prostate specific  antigen (PSA).  Higher than normal PSA levels  can
indicate cancer
•     Bone marrow aspiration
These show a picture of the bone marrow that may be affected in leukemia
and blood cancers.
• Pap test
Pap  test (Pap  smear)  is  a  routine  test  where  a  sample  of  cells  from  a
woman’s cervix is examined under the microscope. This helps identify changes in
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the cells that could indicate  cervical cancer or other conditions. Sputum analysis
and bronchial washing analysis. The cells of the sputum and bronchial secretions
are analyzed under the microscope for signs of lung and other respiratory cancers.
 Imaging studies
There are several imaging techniques. These include X rays, CT scans, MRI
scans  of  various  parts  of  the  body.  X-rays  are  the  most  common  imaging
techniques and they may be made more  specific.  This  is  used for  detection of
stomach and small intestinal growths and cancers. Mammogram is an X-ray of the
breasts  used to screen for and/or detect  breast  lumps and growths.  A  Magnetic
Resonance  Imaging (MRI)  uses  a  powerful  magnetic  field  to  create  detailed
computer images of the body’s soft tissue, large blood vessels and major organs.
Both CT scan and MRI can also be used with contrast radio-labeled dyes to obtain
a more clear and specific picture of the cancer. An Ultrasound uses high-frequency
sound waves to determine if a suspicious lump is solid or fluid. These sound waves
are transmitted into the body and converted into a computerized image. Bone scan
is specifically used to identify and locate new areas of cancer spread to the bone.
Normally a Positron imaging test (PET scan) is used. 
 Genetic analysis
Cytogenetic analysis involves analysis of blood or bone marrow cells for
organizations of chromosomes. This shows up any genetic mutations.
Screening:
Unlike diagnosis efforts prompted by symptoms and medical signs,  cancer
screening  involves  efforts  to  detect  cancer  after  it  has  formed,  but  before  any
noticeable  symptoms  appear.  This  may  involve physical  examination blood or
urine  tests,  or medical  imaging.  Cancer  screening  is  currently  not  possible  for
many  types  of  cancers,  and  even  when  tests  are  available,  they  may  not  be
recommended  for  everyone. Universal  screening or mass  screening  involves
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screening everyone. Selective screening identifies people who are known to be at
higher risk of developing cancer, such as people with a family history of cancer.
Several  factors  are  considered  to  determine  whether  the  benefits  of  screening
outweigh the risks and the costs of screening.
These factors include:
 Possible harms from the screening test: for example, X-ray images involve
exposure to potentially harmful ionizing radiation.
 The likelihood of the test correctly identifying cancer.
 The likelihood of cancer being present: Screening is not normally useful for
rare cancers.
 Possible harms from follow-up procedures.
 Whether suitable treatment is available.
 Whether early detection improves treatment outcomes.
 Whether the cancer will ever need treatment.
 Whether  the  test  is  acceptable  to  the  people:  If  a  screening  test  is  too
burdensomethen people will refuse to participate. 
 Cost of the test.
TREATMENT:
The most common types of cancer treatment, such 
• Surgery
Surgery can be used to diagnose, treat, or even help prevent cancer in some
cases. Most people with cancer will have some type of surgery. It often offers the
greatest chance for cure, especially if the cancer has not spread to other parts of the
body. Cancers can be cured if entirely removed by surgery  removed by surgery but
this is not always possible. When the cancer metastasized to other sites in the body
prior  to  surgery,  complete  surgical  excision  is  usually  impossible.  The goal  of
surgery is to remove the tumor alone or the entire organ.




 Chemotherapy (chemo) is the use of medicines or drugs to treat cancer. It s
the treatment of cancer with cancer with drugs that can destroy cancer cells.  It
mainly refers to cytotoxic drugs affects rapidly dividing cells. Chemotherapy drugs
with cell division in various ways, with duplication of DNA or the separation of the
newly  formed  chromosomes.  Most  chemotherapy  regimens  are  given  in
combination therapy. The treatment of some leukemia and lymphomas requires the
use of high dose chemotherapy and total body irradiation.
Principles of chemotherapy:
Cancer is the controlled growth of calls coupled with malignant behavior,
invasion and metastasis. Cancer is thought to be caused by the interaction between
genetic  susceptibilty  and  environmental  toxins.  Broadly,  most  of  the
chemotherapeutic  drugs,  work  by  impairing  mitosis,  effectively  targeting  fast-
fasting deviding cells. As these drugs cause damage to cells they are termed as
cytotoxic. Some of the drugs cause cells to undergo apoptosis. As chemotherapy
effects  after  cell  division,  tumors  with  high  growth  fraction  (such  as  acute
myelogenous leukemia and aggressive lymphomas,  including hodgkin's  disease)
are more sensitive to chemotherapy, as a larger proportion of the targeted cells are
undergoing cell division at any time. 
 Recently, scientists have identified small pumps on the surface of cancer
cells that actively more chemotherapy from inside the cell to the outside.  Research
on  p-glycoproteins  and  other  such  chemotherapy  efflux  pumps,  is  currently
ongoing.  Medications  to  inhibit  the  function  of  p-glycoprotein  are  undergoing
testing as of june 2007, to enhance the efficacy of chemotherapy.
Treatment schemes:
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There are a number of strategies in the administration of chemotherapeutic
drugs used today. Chemotherapy may be given with a curative intent or it may aim
to prolong life or to palliate symptoms.
 Combined modality chemotherapy  is the use of drugs with other  cancer
treatments , such as radiation therapy or surgery. Combination therapy is a similar
practice  which  involves  treating  a  patients  with  a  number  of  different  drugs
simultaneously. The drugs differ in their mechanism and side effects. The biggest
advantage  is  the  minimizing  the  chances  of  resistances  developing  to  any one
agent.
 Adjuvant chemotherapy can be used when there is little evidence of cancer
present, but there is risk of recurrence. This can help reduce chances of resistance
developing if the tumor does develop. It is also useful in killing any cancerous cells
which have spend to other parts of the body. This is often effective as the newly
growing tumours are fast dividing and therefore very susceptible. In  neoadjuvant
chemotherapy initial chemotherapy is aimed for striking the primary tumor, therby
rendering local therapy less destructive or more effective.
          Palliative chemotherapy  is given without curative intent, but simply to
decrease  tumor  load  and increase  life  expectancy.  For  these  regimens,  a  better
toxicity  profile  is  generally  expected. For  some  cancers,  chemotherapy  can
completely get rid of the cancer with a good chance that it will never come back.
Examples  include  certain  types  of  lymphoma,  leukemia  and  testicular  cancer,
among others. For most cancers that have metastasized (spread beyond the original
cancer site), chemotherapy cannot cure the cancer. However, chemotherapy may be
helpful in shrinking the cancer, improving or completely eliminating distressing
symptoms caused by the cancer for a period of time and helping you live longer. 
The majority of chemotherapeutic drugs can be divided into:
• Alkylating agents,






Topoisomer inhibitors and other antitumour agents all of these drugs affect
cell  division  synthesis  and  function  in  some  way.  Some  newer  agents  do  not
interfere with DNA. These include monoclonal antibodies and new tyrosine inase
inhibitors. In, addition some drugs which modulate tumor cell behavior without
directly  attacking  those  cells.  Harmone  treatments  fall  into  this  category  of
adjuvant therapies.
Alkylating agents:
These agents are so named because of their ability to add alkyl groups to
many  electronegative  grouos  under  conditions  present  in  cells.  Cisplatin  and
carbplatin,  as  well  as  oxaliplatin  are  alkylating  agents.Other  agents  are
mechloethamine,  cyclophosphamide,  chlorambucil.  They  work  by  chemically
modifying a cell’s DNA.
Anti-metabolites:
Anti-metabolites  masquerade  as  purine  or  pyrimide  –  which  become the
building blocks of DNA. They prevent these substances becoming incorporated
into DNA during the “s” phase, stopping normal development and division. They
also affect RNA synthesis. Due to thei efficiency, these drugs are the most widely
used cytostatics.
Antitumor antibiotics: 
The most important immunosuppressant from this group is dactinomycin,
which is used in kidney transplatations.




Radiation therapy uses high-energy particles or waves to destroy or damage
cancer cells. It is one of the most common treatments for cancer, either by itself or
along with other forms of treatment. Radiation therapy also called as radiotherapy
or irradiation, is the use of ionizing radiation to kill cancer cells and shrink tumors.
Radiation therapy can be administered externally via external beam radiotherapy or
internally via branchy therapy. The effects of radiation therapy are localized and
confined to the region being treated. 
Radiation  therapy  injures  or  destroys  cells  in  the  area  being  treated  by
damaging their genetic material, making it impossible for these cells to grow and
divide. Radiation therapy may be used to treat almost every type of solid tumor,
including  cancers  of  the  brain,  breast,  cervix,  larynx,  lung,  pancreas,  prostrate,
skin, stomach, uterus, or soft tissues sarcomas. 
 Targeted Therapy
 Targeted therapy is a newer type of cancer treatment that uses drugs or other
substances to more precisely identify and attack cancer cells, usually while doing
little damage to normal cells. Small molecule targeted therapy drugs are generally
inhibitors of enzymatic domains on mutated, over expressed, or otherwise critical
proteins within the cancer cell. Eg.tyrosine kinase inhibotrs inmatinib and gefitinib.
Monoclonal  antibody  therapy  is  another  in  which  the  therapeutic  agent  is  an
antibody which specially binds to a proteinon the surface of cancer cells.
 Immunotherapy:
It  refers  to  a  diverse set  of  therapeutic  stratagies  designed to  induce the
patient’s own immune system to fight the tumor. Allogenic hematopoietic stem cell
transplantation  can  be  considered  a  form of  immunotherapy,  since  the  donor’s
immune cells will often attack the tumor in phenomenon known as graft-versus-





The  growth  of  some  cancers  can  be  inhibited  by  providing  or  blocking
certain harmones. Common examples of harmone-sensitive tumors includes certain
types  of  breast  and  prostrate  cancer.   Removing  or  blocking  estrogens  or
testosterones  is  often  an  important  additional  treatment.  In  certain  cancers,
administration of harmone agonist.
ETIOLOGY:
 Chemical carcinogens:
Chemical carcinogens that  cause DNA mutations are known as  mutagens
and  mutagens  that  causes  cancers  known  as  carcinogens.  Tobacco  smoking  is
associated with lung cancer and bladder cancer. Prolonged exposure to asbestos
fibers is associated with mesothelioma.
   Ionizing radiation:
Sources  of  ionizing  radiation,  such  as  radon  gas,  can  cause  cancer.
Prolonged exposure to ultraviolet radiation from the sun can lead to melanoma and
other skin malignancies.
 Hormonal imbalances:
Some hormones can act in a similar manner to non-mutagenic carcinogens in
that  they  may  stimulates  excessive  cell  growth.  Examples  is  the  role  of
hyperestrogenic stages in promoting endometrial cancer.
 Immune system dysfunction:
HIV is associated with a number of malignancies, including non-Hodgkin’s
lymphoma, HPV- associated malignancies such as anal cancer and cervical cancer
• Infectious diseases:
The main viruses associated with human cancers are human papillomavirus,
hepatitis C and hepatitis B virus, Epstein-Barr virus, and human T-lymphotropic
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virus. Experimental and epidemiological data imply a causative role for viruses
and  they  appear  to  be  the  second  most  important  risk  factors  for  cancer
development in humans, exceeded only by tobacco usage. Liver cirrhosis, from
chronic viral hepatitis infection or alcoholism, is associated with the development
of liver cancer.
In addition to viruses, researchers have noted a connection between bacteria
and certain cancers. The prominent eg. is chronic infection wall of the stomach
with helicobacter pylori and gastric cancer.   
• Alternative treatments:
Complementary and  alternative  cancer  treatments  are  a  diverse  group of
health  care  systems,  practices,  and  products  that  are  not  part  of  conventional
medicine[51]."Complementary  medicine"  refers  to  methods  and  substances  used
along  with  conventional  medicine,  while  "alternative  medicine"  refers  to
compounds  used  instead  of  conventional  medicine[52].Most  complementary  and
alternative medicines for cancer have not been rigorously studied or tested. Some
alternative treatments have been investigated and shown to be ineffective but still
continue to be marketed and promoted[53].
Prevention of cancer:
         Cancer prevention is defined as active measures to decrease the risk of
cancer. The vast majority of cancer cases are due to environmental risk factors, and
many, but not all, of these environmental factors are controllable lifestyle choices.
Thus,  cancer  is  considered  a  largely preventable  disease.  Greater  than  30% of
cancer  deaths  could  be  prevented  by  avoiding  risk  factors  including:  tobacco,
overweight  /  obesity,  an  insufficient  diet,  physical  inactivity,  alcohol,  sexually
transmitted infections, and air pollution.
        Not all environmental causes are controllable, such as naturally occurring
background radiation,  and  other  cases  of  cancer  are  caused  through  hereditary
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genetic disorders, and thus it is not possible to prevent all cases of cancer.
• Dietary
While many dietary recommendations have been proposed to reduce the risk
of  cancer,  the  evidence  to  support  them is  not  definitive.  The  primary dietary
factors that increase risk are obesity and alcohol consumption; with a diet low in
fruits  and vegetables and high in red meat being implicated but not confirmed.
Consumption  of  coffee  is  associated  with  a  reduced  risk  of  liver  cancer.
Consumption of red or processed meat may lead to an increased risk of breast
cancer, colon cancer, and pancreatic cancer, a phenomenon which could be due to
the presence of carcinogens in meats cooked at high temperatures.
Dietary  recommendations  for  cancer  prevention  typically  include  an
emphasis  on  vegetables,  fruit,  whole  grains,  and  fish,  and  an  avoidance  of
processed and red meat (beef, pork, lamb), animal fats, and refined carbohydrates.
• Medication
The concept that medications can be used to prevent cancer is attractive, and
evidence  supports  their  use  in  a  few  defined  circumstances.  In  the  general
population  NSAIDs  reduce  the  risk  of  colorectal  cancer  however  due  to  the
cardiovascular and gastrointestinal side effects they cause overall harm when used
for prevention. Aspirin has been found to reduce the risk of death from cancer by
about 7%.COX-2 inhibitor may decrease the rate of polyp formation in people with
familial  adenomatous  polyposis  however  are  associated  with  the  same  adverse
effects as NSAIDs. Daily use of tamoxifen or raloxifene has been demonstrated to
reduce the risk of developing breast cancer in high-risk women. The benefit verses
harm for 5-alpha-reductase inhibitor such as finasteride is not clear. Vitamins have
not been found to be effective at preventing cancer, although low blood levels of
vitamin D are correlated with increased cancer risk. Whether this relationship is
causal  and  vitamin  D  supplementation  is  protective  is  not  determined.  Beta-
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Carotene supplementation has been found to increase lung cancer rates in those
who are  high risk.  Folic  acid  supplementation  has  not  been  found effective  in
preventing colon cancer and may increase colon polyps.
• Vaccination
Vaccines  have  been  developed  that  prevent  some  infection  by  some
viruses.Human papillomavirus vaccine (Gardasil and Cervarix) decreases the risk
of  developing  cervical  cancer.  The  hepatitis  B  vaccine  prevents  infection  with
hepatitis B virus and thus decreases the risk of liver cancer.
CANCER PAIN:
People  with  cancer  often  feel  severe  or  constant  pain. The  pain  they
experience depends on the type of cancer they have, the stage the disease is at, and
the  therapy  they  receive.  Approximately  25%  to  50%  of  people  with  cancer
complain of pain at the time of diagnosis, and up to 75% of people with cancer
complain  of  pain  as  the  cancer  progresses.  Cancer  pain  can  be  defined  as  a
complex sensation that reflects both damage to the body and the body's response to
the damage. Pain is one of the major complications of cancer. At any given time,
about half of all patients with malignant cancer are experiencing pain, and more
than  a  third of  those  experience moderate  or  severe  pain  that  diminishes  their
quality of life by adversely affecting mood, sleep, social relations and activities of
daily living[54]. The presence of pain depends on the location of the cancer and the
stage of the disease. Two thirds of patients with advanced stage cancer experience
significant pain[55].
Causes of Cancer Pains:
Most cancer pain is caused by the tumour pressing on bones, nerves or other
organs in your body.  Sometimes  pain is  related to  your  cancer  treatment.   For
example,  some  chemotherapy  drugs  can  cause  numbness  and  tingling  in  your
hands  and  feet  or  a  burning  sensation  at  the  place  where  they  are  injected.
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Radiotherapy can cause skin redness and irritation. Between 40 and 80 percent of
patients with cancer pain experience neuropathic pain[56].
 Cancer pain can be caused by:
 INFECTION:
 Infection of a tumor or its surrounding tissue can cause rapidly escalating
pain, but is sometimes overlooked as a possible cause of pain. 
 TUMOR-RELATED:
Tumors can cause pain by crushing or  infiltrating tissue,  or by releasing
chemicals  that  make  nociceptors  responsive  to  stimuli  that  are  normally  non-
painful.
 VASCULAR EVENTS:
• Deep vein thrombosis
Between 15 and 25 percent of deep vein thrombosis (DVT) is caused by
cancer (often by a tumor compressing a vein). Cancers most likely to cause DVT
are pancreatic cancer, stomach cancer, brain tumors, advanced breast cancer and
advanced pelvic tumors. DVT may be the first hint that cancer is present. It causes
swelling and pain in the legs, especially the calf, and (rarely) in the arms.[57]
  Superior vena cava syndrome
The superior vena cava may be compressed by a tumor, most often non-
small-cell lung carcinoma small-cell lung carcinoma , lymphoma, or metastasis,
causing superior vena cava syndrome. Common symptoms include shortness of




Brain  tissue  itself  contains  no  nociceptors;  brain  tumors  cause  pain  by
pressing  on  blood  vessels  or  the  membrane  that  encapsulates  the  brain,  or
indirectly by causing a build-up of fluid which may compress pain-sensitive tissue.
• Meninges
Ten  percent  of  patients  with  disseminated  cancer  develop  meningeal
carcinomatosis, where metastatic seedlings develop in the meninges (outer lining)
of both the brain and spinal cord (with possible invasion of the brain or spinal
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cord). Melanoma and breast and lung cancer account for 90 percent of such cases.
Back  pain  and  headache  –  often  severe  and  possibly  associated  with  nausea,
vomiting, neck rigidity and pain or discomfort in the eyes due to light exposure
(photophobia) – are frequently the first symptoms of meningeal carcinomatosis.
"Pins and needles" (paresthesia), bowel or bladder dysfunction and lower motor
neuron weakness are common features.[59]
• Spinal cord compression
About three percent of cancer patients experience spinal cord compression,
usually  from  expansion  of  the  vertebral  body  due  to  metastasis,  sometimes
involving collapse of the vertebral body. Occasionally compression is caused by
nonvertebral  metastasis  adjacent  to  the  spinal  cord.  Seventy  percent  of  cases
involve the thoracic, 20 percent the lumbar, and 10 percent the cervical spine; and
about 20 percent of cases involve multiple sites of compression. The nature of the
pain depends on the location of the compression.[60]
• Nerve infiltration or compression
 Infiltration or compression of a nerve by a primary tumor causes peripheral
neuropathy in one to five percent of cancer patients.
• Dorsal root ganglion inflammation
Small-cell lung cancer and, less often, cancer of the breast, colon or ovary
may produce inflammation of the dorsal root ganglia precipitating burning, tingling
pain in the extremities, with occasional "lightning" or lancinating pains.[61]
• Brachial plexopathy
Brachial plexopathy is a common product of Pancoast tumor, lymphoma and
breast cancer, and can produce severe burning dysesthesic pain on the back of the
hand, and cramping, crushing forearm pain.
 BONE:
Invasion  of  bone by cancer  is  the  most  common source  of  cancer  pain.
About 70 percent of breast and prostate cancer patients, and 40 percent of those
with lung, kidney and thyroid cancers develop bone metastases. It is commonly felt
as  tenderness,  with  constant  background  pain  and  instances  of  spontaneous  or
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movement-related exacerbation, and is frequently described as severe. 
Tumors  in  the  marrow  instigate  a  vigorous  immune  response  which
enhances pain sensitivity, and they release chemicals that stimulate nociceptors. As
they grow, tumors compress, consume, infiltrate or cut off blood supply to body
tissues, which can cause pain.[62]
• Fracture
Rib  fractures,  common  in  breast,  prostate  and  other  cancers  with  rib
metastases, can cause brief severe pain on twisting the trunk, coughing, laughing,
breathing deeply or moving between sitting and lying. In breast, prostate or lung
cancer, multiple myeloma and some other cancers, sudden onset limb or back pain
may indicate pathological bone fracture .[63]
• Skull
The base of  the skull  may be affected by metastases  from cancer of the
bronchus, breast or prostate, or cancer may spread directly to this area from the
nasopharynx and this may cause headache, facial paresthesia, dysesthesia or pain,
or cranial nerve dysfunction – the exact symptoms depending on the cranial nerves
impacted.
• Pelvis
Pain produced by cancer within the pelvis varies depending on the affected
tissue, but it frequently radiates diffusely to the upper thigh, and may refer to the
lumbar region. Lumbosacral plexopathy is often caused by recurrence of cancer in
the presacral  space,  and may refer  to the external  genitalia  or  perineum. Local
recurrence of cancer attached to the side of the pelvic wall may cause pain in one
of  the  iliac  fossae.  Pain  on  walking  that  confines  the  patient  to  bed  indicates
possible cancer adherence to or invasion of the iliacus muscle. 
Pain in the hypogastrium (between the navel and pubic bone) is often found
in cancers of the uterus and bladder, and sometimes in colorectal cancer especially
if infiltrating or attached to either uterus or bladder.
• Viscera
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Visceral pain is diffuse and difficult to locate, and is often referred to more
distant, usually superficial, sites.
• Liver
Acute hemorrhage into a hepatocellular carcinoma causes severe upper right
quadrant pain, and may be life-threatening, requiring emergency surgery or other
emergency intervention. A tumor can expand the size of the liver several times and
consequent  stretching  of  its  capsule  can  cause  aching  pain  in  the  right
hypochondrium. 
Other  causes  of  pain  in  enlarged  liver  are  traction  of  the  supporting
ligaments  when standing or  walking,  the  liver  pressing against  the rib  cage or
pinching the wall of the abdomen, and straining the lumbar spine. In some postures
the liver may pinch the parietal peritoneum against the lower rib cage, producing
sharp, transitory pain, relieved by changing position. The tumor may also infiltrate
the liver's capsule, causing dull, and sometimes stabbing pain.
• Kidneys and spleen
Cancer of the kidneys and spleen produces less pain than that caused by liver
tumor – kidney tumors eliciting pain only once the organ has been almost totally
destroyed and the cancer has invaded the surrounding tissue or adjacent pelvis.
Pressure  on  the  kidney  or  ureter  from a  tumor  outside  the  kidney  can  cause
extreme flank pain.
 Local recurrence of cancer after the removal of a kidney can cause pain in
the  lumbar  back,  or  L1  or  L2  spinal  nerve  pain  in  the  groin  or  upper  thigh,
accompanied by weakness and numbness of the iliopsoas muscle, exacerbated by
activity.
 ABDOMINAL AND UROGENITAL HOLLOW ORGANS
Inflammation of artery walls and tissue adjacent to  nerves is  common in
tumors of abdominal and urogenital hollow organs. Infection or cancer may irritate
the trigone of the urinary bladder, causing spasm of the detrusor urinae muscle (the
muscle that squeezes urine from the urinary bladder), resulting in deep pain above
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the pubic bone, possibly referred to the tip of the penis, lasting from a few minutes
to half an hour.
• Gastrointestinal
The  pain  of  intestinal  tumors  may  be  the  result  of  disturbed  motility,
dilation,  altered  blood  flow  or  ulceration.  Malignant  lymphomas  of  the
gastrointestinal  tract  can  produce  large  tumors  with  significant  ulceration  and
bleeding.
• Pancreas
Ten percent of patients with cancer of the pancreatic body or tail experience
pain,  whereas  90  percent  of  those  with  cancer  of  the  pancreatic  head  will,
especially if the tumor is near the hepatopancreatic ampulla. The pain appears on
the left or right upper abdomen, is constant, and increases in intensity over time. It
is  in  some  cases  relieved  by  leaning  forward  and  heightened  by lying  on  the
stomach. Back pain may be present and, if intense, may spread left and right. Back
pain may be referred from the pancreas, or may indicate the cancer has penetrated
paraspinal muscle, or entered the retroperitoneum and paraaortic lymph nodes
• Rectum
A local tumor in the rectum or recurrence involving the presacral plexus may
cause pain normally associated with an urgent need to defecate. This pain may,
rarely, return as phantom pain after surgical removal of the rectum, though pain
within a few weeks of surgical removal of the rectum is usually neuropathic pain
due to the surgery . The emergence of pain on standing or walking (described as
"dragging") may indicate a deeper recurrence involving attachment to muscle or
fascia.
• Serous mucosa
Carcinosis  of  the  peritoneum  may  cause  pain  through  inflammation,
disordered visceral motility, or pressure of the metastases on nerves. Once a tumor
has penetrated or perforated hollow viscera, acute inflammation of the peritoneum
appears,  inducing  severe  abdominal  pain.  Pleural  carcinomatosis  is  normally
painless.




Invasion  of  soft  tissue  by  a  tumor  can  cause  pain  by  inflammatory  or
mechanical stimulation of nociceptors, or destruction of mobile structures such as
ligaments, tendons and skeletal muscles.
ACUTE AND CHRONIC PAIN:
Cancer pain can be acute or chronic. Acute pain is due to damage caused by
an injury and tends to only last a short time. For example, having an operation can
cause  acute  pain.  The  pain  goes  when  the  wound  heals.  In  the  meantime,
painkillers  will  usually keep  it  under control.   Chronic pain is  pain  caused by
changes to nerves. Nerve changes may occur due to cancer pressing on nerves or
due to chemicals produced by a tumour. It can also be caused by nerve changes due
to cancer treatment. The pain continues long after the injury or treatment is over
and can range from mild to severe. It can be there all the time and is also called
persistent pain. Chronic pain can be difficult to treat, but painkillers or other pain
control methods can successfully control it in about 95 out of every 100 people
(95%).
Pain  that  is  not  well  controlled  can  develop  into  chronic  pain.  So  it  is
important to take painkillers that you are prescribed. If there is chronic cancer pain,
and when the pain is not controlled by the medicines that are taken. This is called
breakthrough pain. If regularly painkillers are taken but still get pain at times extra
top up doses of painkillers may be needed. Sometimes pain can come on quickly,
for example when you need to have a dressing changed or move around. This type
of pain is called incident pain.
Physical cancer pain:
 Physical cancer pain has two sources:
• Nociceptive pain refers to pain relayed by nerves with the job of conveying
damage in a part of the body. The pain is usually felt as aching or pressure -
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most cancer pain feels like this. 
• Neuropathic (nerve) pain refers to pain caused by damage inside the nervous
system. The pain is usually felt as sharp shooting and stabbing sensations
TYPES OF CANCER PAIN:
Pain can be described in  different ways.  They may be acute and chronic
pain.  Or  they  may  be  the  body  tissue  your  pain  comes  from.  It  is  extremely
important to find out the type and cause of pain so that they can be treated in the
right way.
Types of pain include:
• Nerve pain
• Bone pain
• Soft tissue pain
• Phantom pain
• Referred pain
•     Nerve pain
Nerve pain is caused by pressure on nerves or the spinal cord, or by damage
to nerves. It is also called neuropathic pain. People often describe nerve pain as
burning, shooting, tingling, or as a feeling of something crawling under their skin.
It can be difficult to describe exactly how it feels. Some people have long term
nerve pain after surgery.  Nerves are cut during surgery and they take a long time to
heal because they grow very slowly. Some people may have pain around their scar
for 2 years or more after their surgery. Nerve pain can also occur after other cancer
treatments such as radiotherapy or chemotherapy.
• Bone pain
Cancer can spread into the bone and cause pain. The cancer may affect one
specific area of bone or several areas. The cancer cells within the bone damage the
bone tissue and cause the pain.  This  pain is  called somatic pain which can be
described as aching, dull or throbbing.
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• Soft tissue pain
Soft tissue pain means pain from a body organ or muscle. For eg, you may
have pain in your back caused by tissue damage to the kidney. This pain can't
always  pinpoint,  but  it  is  usually  described  as  sharp,  cramping,  aching,  or
throbbing. Soft tissue pain is also called visceral pain.
• Phantom pain
Phantom pain means pain in a part of the body that has been removed. For
example,  pain  in  an  arm  or  leg  that  has  been  removed  due  to  sarcoma  or
osteosarcoma. Or pain in the breast area after removal of the breast (mastectomy).
Phantom pain is very real and people sometimes describe it as unbearable.
• Referred pain
Sometimes pain from an organ in the body may be felt in a different part of
the body. This is called referred pain. For example, a swollen liver may cause pain
in the right shoulder, even though the liver is under the ribs on the right side of the
body. This is because the liver presses on nerves that end in the shoulder.
Cancer pain affects quality of life in four main ways:
• physically (people feel weak) 
• psychologically (people feel unable to cope) 
• socially (people's relationships suffer) 
• spiritually (suffering may make people question their beliefs)
TREATMENT FOR CANCER PAIN:
PAIN KILLERS USED:
 Opioids: 
Opioids are  most  commonly used  for  pain  relief  and  while  some of  the
adverse effects seen with initial therapy are short term, some may last for longer
durations, especially when therapy is continued over longer periods. Some of the
opiods  used  for  severe  pain  are  morphine,  diamorphine,  fentanyl,  alfentanil,
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buprenorphine, oxycodone, hydromorphone, methadone and for moderate or mild
pain codeine, tramadol[64].
Some of the adverse effects of opioid use include:
• Nausea and vomiting: 
The use of opioids stimulates opioid receptors present in the gastrointestinal
tract as well as in the vomiting centre of the brain to cause nausea and vomiting. 
• Drowsiness or sedation:
Opioids, and in particular morphine, are known to cause severe sedation and
drowsiness. 
• Skin changes:
An  allergic reaction  called  urticaria may  develop  and  cause  a  skin  rash
characterized  by  red,  itchy,  raised  bumps.  This  is  caused  by  the  release  of
histamine in response to opioid use. 
• Constipation: 
Opioids  cause  sluggish peristaltic  movements  in  the  digestive  tract.  This
causes stasis or loss of movement of the intestinal contents and leads to severe
constipation, especially in the case of long-term use. 
• Respiratory depression: 
The breathing mechanism in response to a low blood oxygen level may be
suppressed.  As  blood  oxygen falls  and  blood carbon  dioxide  rises,  there  is  an
increase in drive for respiration. 
• Psychological effects:
Opioids give rise to a sense of euphoria and may also lead to hallucinations,
delirium, dizziness and confusion. There may be some amount of memory loss and
headache. 
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• Changes in heart rate: 
Heart rate may become either rapid or very slow. Some opioid users may
also develop postural hypotension or a severe fall in blood pressure on standing up
from a sitting or lying position. 
• Spasms: 
Some people  may develop  spasms of  the  ureter  and urinary retention or
biliary colic and spasms of the biliary tree.
Some of the opiods used :
• For severe pain 
morphine,  diamorphine,  fentanyl,  alfentanil,  buprenorphine,
oxycodone, hydromorphone, methadone are used.
• For  moderate or mild pain 
codeine, tramadol are used.
 Non opiods
Non opiods analgesics are useful for acute or chronic pain resulting from a
variety  of  diseases  process  such  as  cancer,  arthritis,  trauma,  surgery.  After  the
administration of  Non-opiods there will not be a need of additional analgesia. they
does  not  produce  physical  or  psychological  dependence  and  therefore  sudden
interruption in treatment does not cause drug withdrawals. Non-opioid analgesics
are pain medications for mild to moderate pain. 
Non-opioid analgesics include NSAIDs, such as ibuprofen, as well as other
analgesics such as acetaminophen and aspirin.  [65]  These medications also include
adjuvant analgesics, which are those that relieve pain even though pain relief is not
their primary purpose. Examples include antidepressants and anticonvulsants, both
regularly used to treat certain types of chronic pain.
   Non-opioid analgesics may be short-acting or long-acting pain medications. They
may  be  taken  alone  for  pain  management,  though  they  may  also  be  taken  in
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combination with opioids to relieve moderate to severe pain.
          A part of analgesics binds to the opioid-receptors and form a separate group. 
Substances with analgesic, antipyretic and antiphlogistic effects
Non-acidic analgesics
o Not anti-inflammatory in therapeutic doses
o Possess  much  lower  plasma  protein-binding  capacities  than  acidic
analgesics
o Are derivatives of phenazone, metamizole, paracetamol
Non-opioid analgesics also used to be referred to as less effective analgesics.
This is not completely correct concerning their properties because particularly in
inflammation-associated nociceptive pain their analgesic effect if often better than
that of strong or moderately strong opioids.
Mechanism of action of non-acidic analgesics:
Rapid penetration through the blood-brain barrier with secondary inhibiton
of nociceptive stimuli induce the release of prostaglandins at spinal cord and CNS
level.
Acid analgesics:
Mechanisms of action of acidic analgesics:
NSAIDs  reduce  prostaglandin  synthesis  by inhibition  of  cyclooxygenase
(COX  1  and  COX  2).
COX 1 
• Activated by physiological stimuli
• Exerts its function in healthy tissues
COX 2
• Activated mainly by inflammation stimuli
• Releases inflammatory mediators
• Occurs physiologically in spinal cord, kidney and uterus
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• Physiological action in adaptation processes (e.g. wound healing)
Inhibition of COX 2 is responsible for the analgesic, antipyretic and anti-
inflammatory effects, side effects are mainly due to inhibition of COX 1. 
Side effects caused by the inhibition of cyclooxygenase:
Prostaglandin effects:
 Decreased secretion of gastric juice
 Cell protection
 Decreased bowel motility
 Increased platelet aggregation by thromboxane A2.
Effect of prostaglandin synthesis inhibitors:
 Increased secretion of gastric juice
 Increased bowel motility
 Decreased renal excretion of sodium ions, water retention
 Oedema
 Inhibition of platelet aggregation
 In case of COX inhibition, the effect of lipoxygenase is activated.
Clinical effects:
 In asthmatic patients, an asthmatic attack may be triggered
 Headaches
 Vertigo
 Gasric mucosa irritation
 Peptic ulceration
 oedema
Possible side effects independent of cyclooxygenase inhibition  
• Toxic damage to bone marrow (aplastic anaemia, thrombocytopenia)





• Last weeks of pregnancy → preterm closure of Botallo's duct.
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• Severe hepatic or  renal dysfunction →  caution is  advised if  NSAIDs are
administered
Drug interactions[66]:
Glucocorticoids Risk of gastro-intestinal complications ↑
Probenecid
(therapy of gout)
Excretion  of  uric  acid  ↑
Excretion of NSAIDs ↓
Saluretics
(to promote uric acid excretion)
Diuretic effect ↓








Cumarin derivatives Anti-coagulation  effect  ↑
Risk of bleeding ↑
ACE  inhibitors Antihypertensive effect ↑
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                                     DRUG PROFILE:
                                               NAPROXEN: 
DECRIPTION: 
It  is  a  non  steroidal  anti-inflammatory  drug  (NSAID).  It  works  by
reducing hormones that cause inflammation and pain in the body. Naproxen is
used to treat pain or inflammation caused by conditions such as cancer, arthritis,
alkylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps.
Chemical name:     Naproxen is (+)-(S)-2-(6-methoxynaphthalen-2-   yl)         
                                 propanoic acid.
 Molecular formula :C14H14O3. 
 Molecular Weight:  Average: 230.2592
          Monoisotopic: 230.094294314
Structure:
Brand name:         Anaprox, Naprelan, Naprosyn, Aleve.
CLINICAL PHARMACOLOGY:[68]
•   Mechanism of action:  
Naproxen is  a  phenylpropionic  acid  derivatives  having analgesic,  anti
inflammatory and anti pyretic activity.  Such activity is thought to be mediated
via inhibition of the enzyme complex prostagladin synthetase with consequent
reduction in the synthesis of prostagladin from arachidonic acid. The onset of
action of  naproxen may be 2  or  more  hopurs  after  oral  administration  with
therpeutics effect persisting for upto 7-8 hours .
•  Absorption:
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It is rapidly and completely absorbed from the gastrointestinal tract with
an in vivo bioavailability of 95%. The different dosage forms of NAPROSYN
are  bioequivalent  in  terms  of  extent  of  absorption (AUC)  and  peak
concentration  (Cmax);  however,  the  products  do  differ  in  their  pattern  of
absorption. These differences between naproxen products are related to both the
chemical form of naproxen used and its formulation. Even with the observed
differences  in  pattern  of  absorption,  the  elimination  half-life  of  naproxen  is
unchanged across products ranging from 12 to 17 hours. Steady-state levels of
naproxen are reached in 4 to 5 days and the degree of naproxen accumulation is
consistent with this half-life
• Distribution
 Naproxen has a volume of distribution of 0.16 L/kg. At therapeutic levels
naproxen is greater than 99% albumin-bound. At doses of naproxen greater than
500 mg/day there is less than proportional increase in plasma levels 
due to an increase in clearance caused by saturation of plasma protein binding at
higher doses (average trough Cs 36.5, 49.2 and 56.4 mg/L with 500, 1000 and
1500 mg daily doses of naproxen, respectively).  The naproxen anion has been
found  in  the  milk  of  lactating  women  at  a  concentration  equivalent  to
approximately 1% of maximum naproxen concentration in plasma.
• Metabolism
                It is extensively metabolized in the liver to 6-0-desmethyl naproxen,
and both parent  and metabolites  do not  induce metabolizing enzymes.  Both
naproxen  and  6-0-desmethyl  naproxen  are  further  metabolized  to  their
respective acylglucuronide conjugated metabolites.
• Excretion
               The clearance of naproxen is 0.13 mL/min/kg. Approximately 95% of
the naproxen from any dose is excreted in the urine, primarily as naproxen ( <
1%), 6-0-desmethyl naproxen ( < 1%) or their conjugates (66% to 92%).  The
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plasma half-life of the naproxen anion in humans ranges from 12 to 17 hours. 
The corresponding half-lives of both naproxen's metabolites and conjugates are
shorter than 12 hours, and their rates of excretion have been found to coincide
closely  with  the  rate  of  naproxen  disappearance  from  the  plasma.  Small
amounts, 3% or less of the administered dose, are excreted in the feces. 
INDICATIONS:
It  is  indicated  for  the  relief  of  symptoms  associated  with  rheumatoid
arthritis, osteoarthritis, juvenile arthritis acute and chronic gout and for cancer
pain.
CONTRAINDICATIONS:
          Active peptic ulceration and sensitivity to naproxen, aspirin, or other non-
steroidal  anti  inflammatory  agents.It  is  contraindicated  in  patients  with
gasterointestinal  ulceration,  haemorrahagic  diathesis  and asthma and in liver
dydfunction.
DOSAGE AND ADMINISTRATION:
 After  observing  the  response  to  initial  therapy  with  NAPROSYN,
ECNAPROSYN,  ANAPROX,  ANAPROX  or  Suspension,  the  dose  and
frequency  should  be  adjusted  to  suit  an  individual  patient's  needs.  The
recommended strategy for initiating therapy is to choose a formulation and a
starting dose likely to be effective for the patient and then adjust the dosage
based on observation of benefit and adverse events. A lower dose should be
considered in patients with renal or hepatic impairment or in elderly patients. 
ROUTE OF ADMINISTRATION:
Use readily available oral tablets, capsules, or liquid. During intervals of
nausea and vomiting, use suppositories, unless the nausea is NSAID related.
Ketorolac tromethamine is the only NSAID available for parenteral use.
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DRUG INTERACTIONS:
                 ACE-inhibitors, Aspirin, Diuretics, Lithium, Methotrexate, Warfarin
ADVERSE REACTIONS:
Body as a Whole: 
          Pain (back), pain, infection, fever, injury (accident), asthenia, pain chest, 
headache , flu syndrome, monilia, neck rigid, pain neck, abdomen enlarged, 
carcinoma, cellulitis, membrane disorder, allergic reaction. 
Gastrointestinal: 
        Nausea, diarrhea, constipation, abdominal pain, flatulence, gastritis, 
vomiting, dysphagia, dyspepsia (14%), heartburn. stomatitis.
Hematologic: 
        Anemia, ecchymosis.
Respiratory: 
       Pharyngitis, rhinitis, sinusitis, bronchitis, cough increased.
Renal: 
       Urinary tract infection, cystitis.   
Dermatologic: 
      Skin rash, skin eruptions, ecchymoses, purpura. 
Metabolic and Nutrition: 
      Peripheral edema, hyperglycemia.
Central Nervous System:  
       Dizziness, paresthesia, insomnia, drowsiness, light headedness. 
Cardiovascular: 
       Hypertension, edema, dyspnea, palpitations.
Musculoskeletal: 
       Cramps(leg), myalgia, joint disorder, tendon disorder.
Special Senses:
       Tinnitus, hearing disturbances, visual disturbances.
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Special Populations
• Pediatric Patients   
                           In pediatric patients aged 5 to 16 years with arthritis, plasma
naproxen levels following a 5 mg/kg single dose of naproxen suspension (see
DOSAGE AND ADMINISTRATION) were found to be similar to those found
in normal adults following a 500 mg dose
• Geriatric Patients
    Studies  indicate that  although total  plasma concentration of  naproxen is
unchanged, the unbound plasma fraction of naproxen is increased in the elderly.
Unbound trough naproxen concentrations in elderly subjects have been reported
to range from 0.12% to 0.19% of total naproxen concentration, compared with
0.05% to 0.075% in younger subjects. 
     The clinical significance of this finding is unclear, although it is possible that
the increase in free naproxen concentration could be associated with an increase
in the rate of adverse events per a given dosage in some elderly patients.
                                          
                                           




                       Flupirtine is an aminopyridine that functions as a centrally acting
non-opioid analgesic. It is unique as a non-opioid, non-NSAID, non-steroidal
analgesic.[67]
chemical name:       ethyl-N-{2-amino-6-(4- fluorophenylmethylamino)  
                                pyridine-3 yl} cabamate
molecular Formula: C15H17F  N4O2
Molecular mass:      304.32 g/mol
Structure:    
Brand names:            katodol, lupirtine.
PHARMACOKINETICS :[69]
• Mechanism of action: 
           Flupirtine is a selective neuronal potassium channel opener that also has
NMD receptor antagonist properties
• Absorption 
          It is completely absorbed from gastrointestinal tract with a bioavailability
of 90% by oral route and 70% by rectal route.
• Distribution 
         Flupirtine  has  large  volume  of  distribution  (Vd)  and  gets  equally
distributed into both extra and intravascular  compartments.  Flupirtine is  80–
84% bound to human albumin. Concentration in CSF is same as that in plasma
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and higher concentration was observed in liver and exocrine glands, whereas
lower concentration was observed in the kidney. The half-life of flupirtine on
oral, intravenous, and rectal administration with 100 mg is 6.5, 8.5, and 10.7. 
• Metabolism and elimination 
          Flupirtine is metabolized in liver to 4-Fluorohippuric and N-acetylated
analogue  by peroxidase enzymes [human myeloperoxidase and horse radish
peroxide (HRP)]. The N-acetylated metabolite retains 20–30% of activity of its
parent compound. The two metabolites are further oxidized and then conjugated
with glycine to form inactive metabolites 72% of the total dose administered
appears in urine as parent drug and its metabolites, whereas 18% is excreted in
feces.
DOSAGE AND ADMINISTRATION: 
        Flupirtine can be administered by oral and rectal routes. It is available as
50 and 100 mg for oral administration. Adult dose is 300–400 mg per day and
can be increased to 600 mg per day. Dose in children is 150–200 mg per day in
3–4 divided doses. 
SPECIAL POPULATIONS:
          Safety of flupirtine in pregnant, lactating women, and children less than 6
years is not established. If indicated in lactating women, breastfeeding should
be stopped. Dose of flupirtine should be reduced to 50% in elderly patients and
those with renal and hepatic impairment.
DRUG INTERACTION:
 Flupirtine has shown to increase warfarin toxicity but the mechanism is
not clear; hence, patients on oral anticoagulant therapy should be monitored for
prothrombin time and increases hepatotoxic potential  of  paracetamol hepatic
transaminases  levels  should  be  monitored  when  both  the  drugs  are  given
concomitantly.  Alcohol  and  sedatives  including  benzodiazepines  potentiate
tiredness dizziness due to flupirtine.
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 CONTRAINDICATION:
 Flupirtine  is  avoided  in  patients  with  history  of  hypersensitivity  to
flupirtine,  hepatic  encephalopathy,  cholestasis,  myasthenia  gravis,  chronic
alcoholism, primary biliary cirrhosis, and liver disease
ADVERSE DRUG REACTIONS:[70]
Fluriptine  is  notably  devoid  of  any  addictive  properties,  negative
psychological or motor function effects, or effects on reproductive function.
 It can be broken up into two categories.
• PERIPHERAL SIDE EFFECT
Blurred visions, Constipation, Diarrhoea, Dry mouth, Flu-like symptoms,
Gastric  and  abdominal  discomfort,  Gastric  fullness,  Heart  burn,  Nausea,
Pruritus, Vomiting
• CARDIOVASCULAR EFFECTS:
 Slight decreases in systolic blood pressure have been reported in patients
receiving chronic flupirtine therapy. Isolated instances of arrhythmias, such as
supravascular extrasystole, arterial fibrillation and left bundle branch block have
been reported during chronic flupirtine therapy. 
• HEPATOTOXICITY:
Elevated  liver  enzymes,  Deterioration  of  hepatic  functions  in  patients
with preexisting liver disease has been noted.
• NEPHROTOXICITY:
 Elevation  in  blood  urea  nitrogen  and  serum  creatinine  have  been
observed.
• CNS SIDE EFFECTS:
Anxiety,  Depression,  Dizziness,  Fatigue,  Hallucination,
Headache,Insomnia, Weakness, Tremors.
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LITERATURE REVIEW
• Heusinger JH et al conducted a study with  1174 patients with pain due
to various causes. Treatment was given, depending on the indication, for
between  3  days  and  8  weeks.  For  both  drugs  rectal  as  well  as  oral
medication was used. It is stated that  Flupirtine proved to be at least as
efficacious as pentazocine and was better tolerated producing about half
as many adverse reactions and about one third of the drop out rate.
• Colin  S. Goodchild  et  al  published  "Combination  Therapy  with
Flupirtine  and  Opioid:  Open-Label  Case  Series  in  the  Treatment  of
Neuropathic  Pain  Associated  with  Cancer"  in  this  Ten  patients  were
recruited.  Only  one  patient  was  withdrawn  because  of  side  effects.
Several pain measurements were used.  There were significant reductions
of average pain (P < 0.01) and neuropathic pain discriminant scores (P <
0.01), as well as an increase in percentage pain relief (P < 0.01). Eight
patients elected to continue to take flupirtine after the trial, two taking
200 mg QID and the others 100 mg QID. Of these eight, six said that
flupirtine was of considerable help and two said it helped a little.. This
short duration open-label study in 10 subjects suggests that flupirtine may
be useful in the treatment of neuropathic pain when used in combination
with opioids.
• Sanja  Perovic et  al  published  "  Flupirtine  increases  the  levels  of
glutathione  and  Bcl-2  in  hNT neurons:  mode  of  action  of  the  drug-
mediated anti-apoptotic effect" in this study hNT neurons were induced to
apoptosis applying glutamate (Glu; at concentrations > or = 1 mM) or
NMDA (> or = 1 mM). During Glu/NMDA-mediated apoptosis the levels
of the intracellular anti-apoptotic agents Bc1-2 and glutathione dropped
by more than 50%. Flupirtine completely abolished this reduction of Bc1-
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2 and glutathione level at a concentration of 10 microM. In the presence
of  3  microM  flupirtine  a  >  6-fold  increase  of  the  Bc1-2  (B-cell
leukemia/lymphoma-2) level was observed in hNT neurons. stated that
the View the MathML source neuronal cell death in vitro is controlled at
least partially by Bcl-2 and glutathione. Neuronal cell death by Glu or
NMDA in vitro can be overcome applying the drug flupirtine which is in
clinical use.
•  Lia.C et al published "Analgesic efficacy and tolerability of flupirtine vs.
tramadol  in  patients  with  subacute  low  back  pain:  a  double-blind
multicentre trial" in this  randomised,  double-blind,  parallel-group trial,
209 LBP patients, aged 18-65 years, were orally treated with flupirtine
100 mg (n = 105) vs. tramadol 50 mg (n = 104), both three times daily for
5-7 day stated Flupirtine 100 mg three times daily was associated with a
reduction in pain and improvements in functional capacity equivalent to
that  observed  with  tramadol  50  mg three  times  daily,  and  was  better
tolerated.
• Jae C.  Chang et  al  published "Utility of  naproxen in  the  differential
diagnosis of fever of undetermined origin in patients with cancer" in this
study Twenty-two patients with cancer and fever of undetermined origin
for more than seven days were treated with naproxen to control fever
when there was no evidence of infection after a careful initial evaluation,
and in most cases, after failure of  antibiotic  therapy.  In final analysis,
none of five patients with infectious fever had responses to naproxen. In
contrast,  14  of  15  patients  with  neoplastic  fever  showed  a  prompt,
complete, and sustained lysis of fever within 24 hours after the initiation
of  naproxen  treatment,  and  the  patients  also  showed  symptomatic
improvement.  stated data suggest that naproxen specifically produces the
lysis of neoplastic fever and, therefore, is a useful agent in assisting in the
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differential diagnosis of infectious fever and neoplastic fever in patients
with cancer and fever of undetermined origin.
• Richard  O  Day et  al  published  "Relationship  of  serum  naproxen
concentration to efficacy in rheumatoid arthritis " in this study Twenty-
four  patients  with  rheumatoid  arthritis  were  tested  in  a  randomized,
double-blind.  Latin-square  comparison  of  250,  750  and  1500  mg  of
naproxen daily. Each  received each dose for 2 wk and baseline disease
activity was established during withdrawal of medication before and after
the  study. stated  Patients  with  a  trough  total  serum  naproxen
concentration under 18 microg/ml did not respond, while 76% of patients
with trough total serum concentrations above 50 microg/ml responded.
No serum naproxen toxicity level relationship was established.
• TSAVARIS.N et al published "A randomized trial of the effect of three
non-steroid  antiinflammatory  agents  in  ameliorating  cancer-induced
fever" in this study  randomized 48 patients to receive three different non-
steroid anti-inflammatory drugs: Naproxen (500 mg d-1), Indomethacin
(75 mg d-1) or Diclophenac sodium (75 mg d-1). All patients had solid
tumours, and microbial infection had been excluded. All three drugs were
equally effective in bringing the temperature down to normal for a period
of 30-33 d.  stated  that Naproxen, Indomethacin and Diclophenac sodium
are equally effective in ameliorating paraneoplastic fever. In relapse, a
second drug given subsequently can be effective as well.
• Vernon E et al published "Chemopreventive Efficacy of Naproxen and
Nitric Oxide–naproxen in Rodent Models of Colon, Urinary Bladder, and
Mammary Cancers" in this study naproxen administered at 200 and 400
ppm in the diet reduced mean ACFs in the colon by about 45% to 60%,
respectively.  NO-naproxen  was  likewise  administered  in  the  diet  at
roughly equimolar doses (300 and 600 ppm) and reduced total ACF by
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20% to 40%, respectively.  In  the hydroxybutyl  (butyl)  nitrosamine rat
urinary bladder cancer model, NO-naproxen was given at 183 or 550 ppm
in the diet, and naproxen at 128 ppm. The NO-naproxen groups had 77%
and  73% decreases,  respectively,  in  the  development  of  large  urinary
bladder  tumors,  whereas  the  128 ppm naproxen group also  showed  a
strong  decrease  (69%).  If  treatments  were  started  3  months  after
hydroxybutyl (butyl) nitrosamine, NO-naproxen (550 ppm) and naproxen
(400  ppm)  were  also  highly  effective  (86-94%  decreases).  In  the
methylnitrosourea-induced mammary cancer model in rats, NO-naproxen
and naproxen showed nonsignificant inhibitions (12% and 24%) at 550
and 400 ppm, respectively. stated that both naproxen and NO-naproxen
are effective agents against urinary bladder and colon, but not mammary,
carcinogenesis.
• Sandy  Srinivas et  al  plublished  "A Phase  II  Trial  of  Calcitriol  and
Naproxen in Recurrent Prostate Cancer" in this study Twenty-one patients
were enrolled in the trial. Four patients met criteria for progression, with
a PSA doubling time (PSADT) that decreased while on therapy. Fourteen
patients had a prolongation of PSADT compared to baseline. This study
stated Combination therapy with weekly calcitriol and daily naproxen is
well tolerated by most patients and prolongation of PSADT was achieved
in 75% of patients.
• Harish S et al published "Flupirtine: Clinical pharmacology" this Study
have  shown  that  flupirtine  reduced  cancer  pain  more  effectively  than
tramadol and pentazocine. Also, the adverse reaction profile was similar
in both flupirtine and tramadol treated patients. But, with an increased
incidence of central  nervous system (CNS) side effects  to pentazocine
when  compared  with  flupirtine which  concluded  Studies  suggest
flupirtine as an effective analgesic for treatment of acute pain states such
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as postoperative pain, traumatic injury, headache, and migraine, as well as
chronic  pain  such  as  musculoskeletal  pain.  It  is  effective  and  better
tolerated for treatment of cancer pain.
• Anton  Kolosov et  al  published  "Flupirtine  Enhances  the  Anti-
Hyperalgesic  Effects  of  Morphine  in  a  Rat  Model  of  Prostate  Bone
Metastasis" in this study Syngeneic prostate cancer cells were injected
into  the  right  tibia  of  male  Wistar  rats  under  anesthesia.  This  led  to
expanding tumor within the bone in 2 weeks, together with the concurrent
development of hyperalgesia to noxious heat. Paw withdrawal thresholds
from noxious heat were measured before and after the maximum non-
sedating  doses  of  morphine  and  flupirtine  given  alone  and  in
combinations which  concluded  The  results  suggest  that  flupirtine  in
combination  with  morphine may be useful  clinically to  provide better
analgesia at lower morphine doses in the management of pain caused by
tumors growing in bone.
• Jacques Devulder et al published "Flupirtine in Pain Management" this
study says  Flupirtine displays indirect NDMA receptor antagonism via
activation  of  potassium  channels  and  is  the  first  representative  of  a
pharmacological class denoted the 'selective neuronal potassium channel
openers'. The generation of the M-current is facilitated by flupirtine via
the  opening  of  neuronal  Kv7  potassium  channels.Neuronal
hyperexcitability is a physiological component of many pain states such
as  chronic  pain,  migraine  and  neurogenic  pain which  concluded
Flupirtine is an analgesic with many potential therapeutic benefits that
may prove useful in the treatment of many disease states
• Elango Panchanathan et al published "Effect of flupirtine on the growth
and viability of U373 malignant glioma cells" this study says Variations
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in  the  growth  of  U373  MG  cells  in  5  mM  N-methyl-D-aspartate
(NMDA),  1  mM  flupirtine,  and  combined  treatment  indicated  the
antagonistic  effects  of  NMDA and  flupirtine  on  MG  cell  lines.  The
variation in the percentage of gated cell population in different cell cycle
phases  showed  significant  variations  after  48  h  of  treatment. which
concluded A previous study compared the analgesic efficacy and safety of
flupirtine with those of pentazocine; the results showed that flupirtine is
significantly more effective and elicits fewer side effects than pentazocine
when these two drugs are used to reduce very severe cancer-induced pain
• Seema  Mishra et  al  published  "Successful  Use  of  Flupirtine  in
Refractory  Neuropathic  Pain  Due  to  Small  Fiber  Neuropathy"  in  this
study  the case of a 22-year-old postoperative case of right frontoparietal
oligodendroglioma  who  received  multiple  drugs  for  his  severe
neuropathic pain without significant relief were taken which concluded
the  pain  almost  completely  subsided  once  flupirtine  was  added  and
substituted for some of the currently recommended first-line drugs.
• Manasi  Banerjee et  al  published "Comparative  study of efficacy and
tolerability  of  flupirtine  versus  tramadol  in  non-steroidal  anti-
inflammatory drug intolerant  mechanical  low back pain" in  this  study
randomized, single-blinded, intention to treat (ITT) trial started with 240
non-steroidal  anti-inflammatory  drug  (NSAID)  intolerant  patients  who
were prescribed either tablet flupirtine (100 mg twice daily) or capsule
tramadol (50 mg twice daily), for 4 weeks. Follow-up was done on days
14,  28  and  4  weeks  after  treatment  completion. which  concluded
Flupirtine has better sustained efficacy and tolerability than tramadol .
• Hoock et  al  published  "Crystalline  form of  flupirtine  ((2-amino-6-(4-
fluoro-benzylamino)-pyridin-3-yl)-carbamic acid ethyl ester)" in this The
invention  relates  to  novel  multicomponent  crystals,  to  the  production
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thereof, and to the use thereof for treating pain conditions, in particular of
unclear genesis, by means of a simultaneous effect on pains which are
caused by muscle tension or  degenerative joint diseases as well  as on
pains that are based on inflammatory processes which concluded it is a
centrally acting non-opioid analgesic which is devoid of the typical side
effects of natural or synthetic opioids.
• Bergmann JF et al published "A randomised clinical trial of the effect of
informed consent on the analgesic activity of placebo and naproxen in
cancer pain" this is a randomized study in which Forty-nine patients with
mild  or  moderate  cancer  pain  which  did  not  need  narcotic  analgesics
entered  the  study.  Twenty-five  received  both  treatments  without  any
information  and constituted  the  uninformed  group.  Twenty-four  had  a
complete information about the trial; six refused to participate. The 18
others constituted the informed-consent group. Visual analogue scales of
pain before and 30, 60, 120 and 180 min after the intake of naproxen and
placebo  were  recorded.  this  concluded   that,  in  contrast  with  parallel
studies, giving information in a crossover, placebo-controlled trial may
increase the apparent efficacy of both the tested agent and the placebo,
and decrease the perceived difference the two.
• Stanley Levick et al published "Naproxen sodium in treatment of bone
pain  due  to  metastatic  cancer"this  is  a  randomized,  parallel  study
compared the efficacy and safety of  two dosages  of  naproxen sodium
(NS) in 100 patients with bone pain due to metastatic cancer. Patients
were asked to rate their pain on a scale of 0–99; those patients with pain
scores of 40 or more (indicating moderate to severe pain) were enrolled
which concluded  During use of NS, pain intensity scores decreased by
approximately one-third in each treatment group.
• Ventafridda et al published "Sodium naproxen versus sodium diclofenac
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in cancer pain control" this is a single-blind random study, simultaneously
carried  out  by  five  Pain  Therapy  and  Palliative  Care  Centres,  the
analgesic power and side-effects of sodium naproxen (CAS 26159-34-2)
and sodium diclofenac (CAS 15307-86-5) by mouth were compared in a
group of 100 advanced cancer patients which concluded that the similar
analgesic effect of the two drugs--pain intensity and duration decreased
by half in the first week of treatment--and a comparatively low morbidity
rate.
• Gallucci  M et  al  published "Nimesulide in  the treatment  of  advanced
cancer pain. Double-blind comparison with naproxen." This Is a clinical
double-blind  study,  the  analgesic  efficacy  and  the  side-effects  of
nimesulide (Aulin, CAS 51803-78-2) and naproxen administered to 68
patients affected by advanced cancer pain were compared. Patients were
treated with non-steroidal anti-inflammatory drugs according to the first
step  of  the  pharmacological  analgesic  scale  of  the  WHO. This  is
concluded  drugs resulted to be effective with a low incidence of adverse
events that may be related to their use.
• Ronald  A.  Lubet et  al  published  "Screening  Agents  for  Preventive
Efficacy  in  a  Bladder  Cancer  Model:  Study  Design,  End  Points,  and
Gefitinib and Naproxen Efficacy" in this study low and high dose aspirin
altered the formation of large bladder tumors by 87% (decreased), 90%
(decreased),  3%  (increased),  6%  (decreased)  and  60%  (decreased),
respectively.  Using  protocol  2  Iressa  and  naproxen  were  also  highly
effective.  Protocol  3  evaluation  revealed  that  only  Iressa  caused  a
significant  decrease  in  microscopic  bladder  cancers  (63%). This
concluded an established cancer end point appears preferable. Naproxen,
which has an excellent cardiovascular profile, or epidermal growth factor
receptor inhibitors may be effective in an adjuvant setting.
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• Stefan Grond et al published "Assessment and treatment of neuropathic
cancer pain following WHO guidelines"in this study  The present study
surveys 593 cancer patients treated by a pain service following the WHO
guidelines  for  relief  of  cancer  pain.  Of  these,  380  presented  with
nociceptive, 32 with neuropathic and 181 with mixed (nociceptive and
neuropathic) pain. In patients with nociceptive, mixed and neuropathic
pain, the average duration of evaluated pain treatment was 51, 53 and 38
days, respectively. which concluded that neuropathic cancer pain is not
intractable  and  can  be  relieved  in  the  majority  of  patients  using
analgesics.
• Ewan Mc Nicol et al published "Nonsteroidal Anti-Inflammatory Drugs,
Alone or Combined With Opioids, for Cancer Pain" in this study Forty-
two trials involving 3,084 patients met inclusion criteria: eight compared
NSAID  with  placebo;  13  compared  one  NSAID  with  another;  23
compared  NSAID with  opioid,  NSAID or  opioid  versus  NSAID plus
opioid combinations, or NSAID plus opioid combinations versus NSAID
plus  opioid  combinations;  and  nine  studies  assessed  the  effect  of
increasing NSAID dose. This concluded studies demonstrated increased
efficacy with increased NSAID dose, without dose-dependent increases
in side effects.
• Motsch.J et al published "α-Adrenergic Agonists in Pain Therapy" this
study is to   investigate whether the stimulation of beta(2)-ARs could in
fact  be  adequate  to  alleviateneuropathic allodynia.  Neuropathy  was
induced in mice by sciatic nerve cuffing. We demonstrate that chronic but
not acute stimulation of beta(2)-ARs with agonists such as clenbuterol,
formoterol,  metaproterenol  and  procaterol  suppressed neuropathic
allodynia. This concluded α-Adrenergic agonists such as flupirtine have
recently become of interest to pain therapists and anesthesiologists, since
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drugs  of  this  class  exhibit  analgesic,  sedative,  anesthetic-sparing,  and
hemodynamic-stabilizing properties.
• Mercadante.S et  al  published "The use of  anti-inflammatory drugs in
cancer pain" this study says The role of non-steroidal anti-inflammatory
drugs (NSAIDs) in cancer pain has been well established in the treatment
of  mild pain and  also  alone  or  in  association  with  opioids  for  the
treatment of moderate to severe pain. Acutely, NSAIDs may be more than
mild analgesics, and may provide additional analgesia when combined
with opioids.this concluded The role of non-steroidal anti-inflammatory
drugs (NSAIDs) in cancer pain has been well established in the treatment
of  mild  pain  and  also  alone  or  in  association  with  opioids  for  the
treatment of moderate to severe pain.
• Martino G et al published "A controlled study of the analgetic effect of
two non-steroidal anti-inflammatory drugs in cancer pain." this is double-
blind  cross-over  trial  was  carried  out  in  18  patients  of  both  sexes
suffering from pain due to malignant tumours who received single doses
of 200 mg indoprofen and 250 mg naproxen p.o. Both compounds were
efficacious and there was no difference in the duration of their activity in
spite of the great difference between their half-lives.Boris Zernikow et al
published "Paediatric cancer pain management using the WHO analgesic
ladder  results of a prospective analysis from 2265 treatment days during
a quality improvement study" this study says Two hundred and twenty
four patients (median age, 9 years; range 0.2-32.1) were enrolled. Three
hundred  and  thirty  three  pain  episodes  comprising  a  total  of  2265
treatment days were documented which concluded  there is no evidence
that a combination of an opioid with a non-opioid is more effective than
opioid therapy alone in in-patient paediatric oncology pain treatment.
• Rianne de Wit et al published "The Treatment of Chronic Cancer Pain in
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a Cancer Hospital in the Netherlands" this is a  prospective study of 313
Dutch cancer patients with chronic pain, the practice of pain treatment
was  evaluated  by  means  of  Donabedian's  structure-process-outcome
framework. The  practice  of  pain  treatment  concluded  that  After
discharge, only 36.8% of the district nurses were informed about patients’
pain.  These  results  emphasize  that  continuing  efforts  to  improve  the
practice of pain treatments are needed.
• Goodchild C et al published "Synergistic Interactions Between a KCNQ
Channel  Opener  and an  Opioid:  Flupirtine  and Morphine  in  Rat  Pain
Models Including Neuropathic Pain" Experiments were performed in rats
in an observer blinded fashion with vehicle controls.  which concluded
Flupirtine should be investigated as an adjunct analgesic with opioids for
the management of patients with severe pain states.
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AIM and OBJECTIVE:
  AIM:           
            The aim of this study is to compare the efficacy and safety of Naproxen
and Flupiritin in cancer patients.
OBJECTIVES:                              
 To measure the pain intensity in cancer patients
 To  compare  the  effectiveness  and  safety  of  pain  therapies  in  cancer
patients using pain rating scales.
 To monitor the adverse drug reactions and their management in cancer
patients.
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PLAN OF WORK:
                           
The entire study was carried out for a period of nine months from june
2013 to feb 2014 in Meenakshi mission hospital and research centre, Madurai.
The proposal was designed as given below.
  June - July 2013
 Literature survey.
 Obtaining consent from the hospital authority.
 Study design including design of data entry form.
 August - December 2013
 Selection of patients
 Obtaining consent from patients.
 Collection of patient detail
 Collection of lab datas
 January - February 2014
 Compilation.
 statistical analysis  
 Submission of reports.
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METHODOLOGY
 SITE OF THE STUDY:
           The study was carried out in Meenakshi mission hospital and research
centre,  Madurai  from  july  2012  onwards.  The  hospital  is  unique  and  well
known for its service to people who come from all over the southern district
and various parts of the state.
Department selected for study in the Hospital:
          Both inpatients and outpatients from the Oncology departments.
PATIENT SELECTION:
 Inclusion criteria:
• Patients of both genders and aged above 20 years having 
    - pain related to cancer 
• And only those patients who are willing to give consent. 
 Exclusion criteria: 
 Pregnant and lactating women
 Previous history of allergy to Flupirtine / Naproxen.
 Non solid tumors
 Patients with conditions like renal failure.
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STUDY GROUPS:
  Patients grouped into two categories
                       Group A
                       Group B
 Group A = Cancer patients received Flupirtine.
 Group B = Cancer patients received Naproxen .
 Patients Enrollment = 30 (A) + 30 (B) =60
STUDY DESIGN:
DESIGN OF DATA ENTRY FORMAT (PROFORMA)
•   A separate data entry format [proforma] for incorporating patient’s details
was designed. The format contains details as follows. 
Proforma I




 Pain Rating Scale
Proforma IV
 Adverse Reaction Monitoring.
Proforma V
 Patient satisfaction scale report. 
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OBSERVATION AND RESULTS:
POPULATION AMONG THE GROUP:
S
S.NO
     GROUPS NO.OF 
PATIENTS
PERCENTAGE
           %




           30             50
2




          30             50
      3        Total            60            100
Table no. 1




















AGE WISE DISTRIBUTION GROUP  (A): `
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TYPES OF CANCER


















   
21 – 30
     
4
     
2
   
6
   
31 - 40 
     
5
   
5
   
41 – 50
     
3
     
2
   
11
   
51 – 60
     
2
     
6
    
4
   
61 – 70
     
2
     
2
     
2
    
4
                                                                               TOTAL
    
30
Table 2
























AGE WISE DISTRIBUTION GROUP (B):
Department of Pharmacy Practice Page 79
Observation and Results
TYPES OF CANCER
   
AGE IN YEARS













     
2
    
2
     
4
   
31 - 40 
     
5
     
5
   
41 – 50
    
4
     
2
     
6
   
51 - 60
     
1
     
3
     
2
     
2
     
8
   
61 - 70
     
3
     
2
     
2
      
7
                                                                               TOTAL
    
30
Table 3
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NO. OF PATIENTS   PERCENTAGE









































GENDER WISE DISTRIBUTION GROUP (B):
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S.NO GENDER NO. OF PATIENTS PERCENTAGE
            %




    
17
        
56.6




    
13
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GROUP (A)
        
VEGETARIAN 5
        
MIXED DIET 25
        
TOBACCO USE 16
        
ALCOHOL USE 6
Table 6
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 GROUP (B):         
VEGE
TARIAN     4



























           GROUP (A):
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S.NO PARTS   AFFECTED NO. OF PATIENTS
     1        BREAST
12
     2        LUNG 
8
    3        CERVICAL 
4
    4        TONGUE
2





S.NO PARTS AFFECTED NO. OF PATIENTS
       1 BREAST           8
      2     LUNGS           8
     3       CERVICAL          4
     4       TONGUE          4
     5      LEUKEMIA           6
   Table 9:
PARTS AFFECTED:
 GROUP (A):
Department of Pharmacy Practice Page 85
Observation and Results























Department of Pharmacy Practice Page 86
Observation and Results























PAIN RATING SCALE:  GROUP (A):
 Pain rating scale:0  1 2 3 4 5 6 7 8 9 10
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    1
     
A1
    
10
     
7
     
3
    
2
     
A2
     
8
     
5
     
2
    
3
     
A3
     
9
     
4
     
2
    
4
     
A4
     
6
     
3
     
1
    
5
     
A5
     
7
     
4
     
1
    
6
     
A6
     
9
     
5
     
2
    
7
     
A7
     
6
     
3
     
1
    
8
     
A8
     
4
     
2
     
0
 9
     
A9
    
10
     
7
     
3
   
10
     
A10
     
5
     
3
     
0
   
11
     
A11
     
8
     
4
     
2
   
12
     
A12
     
9
     
6
     
3
   
13
     
A13
     
8
     
5
     
3
   
14
     
A14
     
6
     
3
     
1
   
15
     
A15
     
7
     
4
     
1
    
16
    
A16
    
10
    
8
    
3
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17
    
A17
    
8
    
5
     
2
    
18
    
A18
    
9
    
5
     
2
    
19
    
A19
    
7
    
3














    
21
    
A21
     
8
    
4
     
1
    
22
    
A21
    
5
     
2
     
0
    
23
    
A23
    
8
     
5
     
2
    
24
    
A24
     
5
     
3
     
0
    
25
    
A25
     
6
     
3
     
1
    
26
    
A26
    
10
     
7
     
3
    
27
    
A27
    
9
     
6
     
3
    
28
    
A28
    
6
     
3
     
1
    
29
    
A29
   
10
     
6
     
2
    
30
    
A30
    
9
     
5
      
3
Table 10
MEAN PAIN INTENSITY SCORE:
Effect of naproxen in Group A :
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PAIN RATING SCALE:   GROUP (B):
 Pain rating scale:0  1 2 3 4 5 6 7 8 9 10
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1
     
B1
    
10
     
7
     
3
    
2
     
B2
     
8
     
5
     
2
    
3
     
B3
     
9
     
4
     
2
    
4
     
B4
     
6
     
3
     
1
    
5
     
B5
     
7
     
4
     
1
    
6
     
B6
     
9
     
5
     
2
    
7
     
B7
     
6
     
3
     
1
    
8
     
B8
     
4
     
2





     
B9
    
10
     
7
     
3
   
10
    
B10
     
5
     
3
     
0
   
11
     
B11
     
8
     
4
     
2
   
12
     
B12
     
9
     
6
     
3
   
13
     
B13
     
8
     
5
     
3




     
6
     
3
     
1
   
15
     
B15
     
7
     
4
     
1
    
16
    
B16
    
10
    
8
    
3
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17
    
B17
    
8
    
5
     
2
    
18
    
B18
    
9
    
5
     
2
    
19
    
B19
    
7
    
3














    
21
    
B21
     
8
    
4
     
1
    
22
    
B21
    
5
     
2
     
0
    
23
    
B23
    
8
     
5
     
2
    
24
    
B24
     
5
     
3
     
0
    
25
    
B25
     
6
     
3
     
1
    
26
    
B26
    
10
     
7
     
3
    
27
    
B27
    
9
     
6
     
3
    
28
    
B28
    
6
     
3
     
1
    
29
    
B29
   
10
     
6
     
2
    
30
    
B30
    
9
     
5
      
3
Table 11
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MEAN PAIN INTENSITY SCORE
Effect of in flupirtine Group B :
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ADVERSE REACTION MONITORING (GROUP A)  :
NO Symptoms Review I Review II 
      
1






      
2






      
3






      
4






       
5






       
6






       
7
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NAUSEA HEADACHE DIZZINESS DROWSINESS








NAUSEA HEADACHE DIZZINESS DROWSINESS
VERTIGO PRURITUS HEART BURN
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ADVERSE REACTION MONITORING (GROUP B)  :
S.NO Symptoms Review I Review II 
      
1






      
2






      
3






      
4






       
5






       
6






       
7




                             Table 13
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NAUSEA HEADACHE DIZZINESS DROWSINESS INSOMNIA








NAUSEA HEADACHE DIZZINESS DROWSINESS INSOMNIA
VERTIGO PRURITUS CONSTIPATION HEART BURN PUD
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PATIENT  SATISFACTION SCALE GROUP “A”
1 2 3 4 5
1-very satisfied , 2-Somewhat satisfied ,  3-Neither satisfied nor dissatisfied
4-Somewhat dissatisfied , 5-Very dissatisfied.
  Serial  no.   Patient ID   Review I   Review II
1 A1 1 1
2 A2 2 1
3 A3 4 3
4 A4 2 1
5 A5 5 5
6 A6 5 5
7 A7 1 1
8 A8 2 2
9 A9 4 3
10 A10 3 2
11 A11 5 5
12 A12 5 4
13 A13 4 4
14 A14 4 4
15 A15 4 3
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16 A16 4 3
17 A17 4 4
18 A18 3 2
19 A19 5 4
20 A20 5 4
21 A21 3 1
22 A22 4 3
23 A23 3 2
24 A24 4 3
25 A25 5 5
26 A26 3 3
27 A27 3 2
28 A28 4 4
29 A29 5 5
30 A30 4 3
 31 Mean± SD 3.667±1.184 3.607±1.337**
* 
P value < 0.0001 ,*** very highly significant by paired t test 
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PATIENT  SATISFACTION SCALE GROUP “B”
                                     1 2 3 4 5
1-very satisfied , 2-Somewhat satisfied ,  3-Neither satisfied nor dissatisfied
4-Somewhat dissatisfied , 5-Very dissatisfied.
Seria
l    
no.    
Patient ID Review I Review II
     1 B1 2 2 
     2 B2 2 2 
      3 B3 1 1 
    4   B4 1 1 
     5 B5 2 1 
     6   B6 3 2 
     7 B7 1 1
     8 B8 1 1
     9 B9 3 2
    10 B10 2 1
    11 B11 2 1
    12 B12 1 1
13 B13 3 2 
14 B14 2 1 
15 B15 5 5 
Department of Pharmacy Practice Page 100
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16 B16 2 1 
17 B17 2 2 
18 B18 2 1 
19 B19 2 1 
20 B20 2 2 
21 B21 3 1 
22 B22 2 2 
23 B23 5 4 
24 B24 3 2 
26 B26 3 1 
25 B25 2 1 
27 B26 3 1 
28 B28 3 2 
29 B29 2 1 
30 B30 1 1 
31 Mean ± SD 2.533 ± 1.120 1.711 ± 1.160***
P value < 0.0001 ,*** very highly significant by paired t test
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Mean Patient satisfaction scale report
Group A 
Data presented are mean ± SD analysis of data done by paired t test. The report shows very highly 
significant *** value for review II compared to review I.
Mean Patient satisfaction scale report
Group B
Data presented are mean ± SD analysis of data done by paired t test. The report shows very 
highly significant *** value for review II compared to review I.












































 Demographic data:  
  In this study,
•     Patients at the age of age between 51 - 60 are at increases risk  
       for cancer
•     CA lungs predominantly affect men than women.
•     Major diagnosis in both group A and group B - CA breast          
  Comparative data:
   In Group A:
•      Before therapy about 76% (n=23) of the patients were
       complained of severe pain
•     About 24% (n=7) complained of moderate pain.
In  patients  with  severe  pain  only  27%  (n=6)  of  the  patients  were
recovered by Naproxen and the remaining 73%(n=17) were not. But in the case
of patients with moderate pain about 85% (n=12) of the patients were recovered
by Naproxen therapy and only 15% (n=1) were not recovered.
 In group B:
• Before therapy about 71 % (n=32) of the patients were complained of severe
pain.
• About 29% (n=13) pf the patients were complained of moderate pain
In  patients  with  severe  pain  about  82  %  (n=26)  of  the  patients  were
recovered by flupirtine  therapy and only 18% (n=6)  were  not  recovered.  In
patients with moderate pain about 98% (n=12) of the patients were recovered by
flupirtine therapy and only 2% (n=1) were not recovered. 
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Moreover, in group A only 17% of the patients are satisfied with Naproxen
therapy.  But  in  group B about  60 % of  the  patients  are  very satisfied  with
flupirtine therapy.
ADVERSE DRUG REACTION:
 Major  adverse  drug  reaction  occurred  in  group  A  who  received
Naproxen and Group B who received flupirtine are dizziness, loss of
appetite,  nausea,  vomiting etc.
 Nausea is more pronounced in cancer patients.
 None  of  the  patients  have  complaint  of  PUD,  and  constipation  or
insomnia.     
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CONCLUSION
     From this study we clearly conclude that,
• Age 51-60 is at high risk of cancer.
• Lung cancer is more prevalent in men than in women.
• CA breast are more prevalent in women.
• According to the results, flupirtine is very effective and safety in the 
management of cancer pain compared to Naproxen.
• More number of patients are very satisfied with flupirtine in group B than
Group A who were given with Naproxen.
• Adverse reactions are common in both the groups. Major adverse drug 
reactions occurred are dizziness, drowsiness, nausea, vomiting etc.
• The final conclusion of this study is that flupirtine is very effective and 
safe in the management of severe cancer pain compared to Naproxen.
• Naproxen is also effective and safe in the management of moderate pain 
in cancer patients.           
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